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ABSTRACT 
 
This dissertation includes three manuscripts describing the use of systemic and intra-vaginal 
antibiotics in non-pregnant women. The first manuscript described the scope of antibiotic use 
and showed that the antibiotic use rate was high. Nearly half of the antibiotics were used to treat 
genitourinary infections. However, one in five antibiotics were used to treat upper respiratory 
tract illnesses for which antibiotics are not indicated according to CDC recommendations and 
these antibiotics were primarily β-lactam agents. 
The second manuscript evaluated whether antibiotic use impacted vaginal and rectal 
colonization by hydrogen peroxide (H2O2)-producing lactobacilli, which are the predominant 
members of the healthy vaginal microbiome. These analyses showed there was a s ignificant 
reduction in vaginal colonization by H2O2-producing lactobacilli following the use of β-lactam 
antibiotics, while other classes of antibiotics had no m easurable effect on Lactobacillus 
colonization. A novel finding was that β-lactam use also reduced rectal colonization by 
lactobacilli to a similar degree as that observed for the vagina and that the effects persisted for a 
longer period of time. 
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 The third manuscript evaluated whether antibiotic use was associated with acquisition of 
vaginal yeast infections. Antibiotic use was associated with increased acquisition of yeast 
vaginitis, and while the highest risk was associated with the use of β-lactam antibiotics, the use 
of some other classes of antibiotics, including metronidazole, fluoroquinolones, and 
nitrofurantoin, were also associated with increased yeast vaginitis. 
Each manuscript provided new insights into the public health significance of antibiotic 
use in reproductive-aged women. The first confirmed that antibiotic use was common in women 
and extended our knowledge by showing that the treatment of genitourinary tract infections was 
the primary indication for antibiotic use and that treatment of upper respiratory tract infections 
was the major contributor to exposure of women to β-lactam antibiotics. The results of the 
second and third manuscripts suggest that decreasing the inappropriate use of β-lactam 
antibiotics deserve special attention since β-lactams were associated with decreased colonization 
by beneficial lactobacilli and increased yeast vaginitis. This research has provided insights on 
how efforts to reduce antibiotic use should be tailored in young women for the greatest public 
health benefit. 
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1.0 INTRODUCTION 
 
 
In the early 1900’s, the leading cause of mortality in the United States was infectious diseases. 
From 1938 t o 1952, t here was a rapid decline in infectious disease mortality rates which was 
partially attributable to the introduction of antimicrobials in clinical care; sulfonamides in 1935 
and antibiotics in 1941.1, 2 While antibiotics have been beneficial in treating infections due to 
pathogenic bacteria, inappropriate antibiotic use in humans and in commercial agriculture has 
contributed to a new public health threat, the emergence of antibiotic resistant bacteria. The 
Centers for Disease Control and Prevention (CDC) estimate that antibiotic resistant infections 
cause more than 2 million illnesses and 23,000 deaths per year in the United States.3  Methicillin-
resistant Staphylococcus aureus (MRSA) is the most common antibiotic-resistant pathogen 
identified in hospitals and accounted for 278,000 hospitalizations in the United States in 2005.4 
The proportion of S. aureus isolates from intensive care unit patients that were MRSA nearly 
doubled between 1992 a nd 2003 f rom 36% to 64%, respectively.5 Similar trends have been 
identified for other important pathogens such as E. coli, the most common cause of bloodstream 
infections, Streptococcus pneumoniae, a common cause of respiratory tract infections6, 7, and 
Neisseria gonorrhoeae, a sexually transmitted infection.8 To address this problem, the CDC 
launched a national campaign in 1995 to promote appropriate antibiotic use.9 However, in spite 
of the recognized impact of inappropriate antibiotic use, antibiotics were prescribed in 10% of all 
ambulatory visits among adults from 2007 to 2009, and during 46% of visits for respiratory 
conditions where antibiotics are rarely indicated.10 These data suggest that inappropriate 
antibiotic use is still prevalent. 
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In addition to contributing to an increase in multidrug resistant pathogens, antibiotic use 
can also have a deleterious impact on commensal bacteria which colonize the mucosal and skin 
surfaces of humans, such as the gastrointestinal, respiratory and reproductive tracts. The critical 
role of the human microbiome in human health has been increasingly recognized.11 Disturbance 
of the microbiome following antibiotic use can allow the overgrowth of pathogens which can 
cause life-threatening infections.  The most well characterized example of this is the disturbance 
of the normal intestinal microflora that leads to antibiotic-associated diarrhea and the increased 
incidence of pseudomembranous colitis associated with Clostridium difficile following antibiotic 
therapy.12, 13 Fecal transplants are a safe and effective mechanism to replenish the gut microflora 
as an adjunctive treatment for this syndrome.13 The detrimental impact of antibiotics on 
beneficial vaginal bacterial such as lactobacilli has also been documented.14 However, few 
studies have evaluated the effect of antibiotic use on the commensal bacteria of the vagina and 
rectum. 
Lactobacillus species are the predominant bacteria in the vagina, and Lactobacillus 
crispatus have been shown to be an important predictor of a stable vaginal microbiome.15 
Lactobacilli produce lactic acid which maintains an acidic environment in the vagina, and some 
species produce hydrogen peroxide which is toxic to other organisms. These metabolic products 
are thought to protect the vagina from colonization by pathogenic bacteria. Women who harbor 
hydrogen peroxide–producing lactobacilli in the vagina and/or the rectum have a reduced 
incidence of bacterial vaginosis, which is the most common vaginal syndrome among 
reproductive-age women.16, 17 Bacterial vaginosis is characterized by the absence of lactobacilli 
and the overgrowth of Gardnerella vaginalis and a d iverse group of anaerobic bacteria, and is 
associated with increased acquisition of sexually transmitted infections including human 
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immunodeficiency virus (HIV), herpes simplex virus type 2, N. gonorrhoeae, Chlamydia 
trachomatis, and Trichomonas vaginalis.18-22 There have been few studies which evaluated the 
effect of antimicrobial use on vaginal colonization by Lactobacillus beyond those used for the 
treatment of bacterial vaginosis.23, 24 Many of the published studies are small and have 
conflicting results.14, 25-32 Therefore, it is unclear whether antibiotics being used for other 
indications in women are having a deleterious impact on vaginal lactobacilli and thereby 
increasing their risk for acquiring vaginal infections. 
Vulvovaginal candidiasis (VVC) is a common cause of vaginitis symptoms among 
women of reproductive age and is characterized by vulvar itching. It is estimated that as many as 
three out of four women will have VVC at least once in their lifetime.33 The prevalence of yeast 
colonization, primarily by Candida species, is 20-25% among women of childbearing age with 
vaginal symptoms, while 10% of women are asymptomatically colonized by yeast in the 
vagina.34, 35 Among women reporting an initial yeast infection, 10-25% reported four or more 
recurrent infections per year.36 Based on 1995 estimates, the annual cost of clinical visits and 
treatment for VVC is projected to be $3.1 billion in 2014.37 In addition to the discomfort and 
costs associated with VVC, some prospective studies have shown an increased risk of HIV 
acquisition among women who had VVC at the visit prior to sero-conversion.38, 39  While the 
pathogenesis of VVC remains unclear, several risk factors have been identified including 
systemic antimicrobial use and absence of vaginal Lactobacillus colonization.33 However, the 
results regarding antimicrobial use as a risk factor for incident vulvovaginal candidiasis have 
been inconsistent across studies.40-48 
In 2010, there were 801 antibiotic prescriptions per 1000 persons in the United States.49 
While antibiotic prescribing patterns have been frequently described in outpatient and inpatient 
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hospital populations, children, and the elderly, there are few reports about antibiotic use 
specifically in women.50-55 A study of antibiotic prescribing patterns in general practices in the 
United Kingdom, reported that 39% of all females, including children, were prescribed an 
antibiotic in 1996 for an overall rate of 852 per 1000 patient years which was higher than the rate 
in males (607 per 1000 patient years).56 Two European studies that compared antibiotic use 
during pregnancy with the year prior to pregnancy found that antibiotic prescribing was higher 
during the non-pregnant period.57, 58 Studies on antibiotic prescribing patterns in non-pregnant 
women are needed in order to understand the burden of antibiotic use in this population and their 
potential for adversely affecting the indigenous vaginal microflora and subsequently increasing 
the risk for acquiring vaginal infections such as VVC, bacterial vaginosis, and HIV. 
The objective of the present research is to describe the frequency of and reason for 
antimicrobial use in healthy, non-pregnant women, identify demographic and behavioral factors 
associated with antibiotic use and to characterize the impact of antibiotic use on vaginal and 
rectal colonization by Lactobacillus spp. and on developing vulvovaginal candidiasis. These 
analyses will provide novel insights into the impact of antibiotic use on colonization by 
commensal lactobacilli associated with health, and the impact of antibiotic use on yeast vaginitis. 
The following review is an overview of the published literature describing the burden of 
antibiotic use in the United States, the in vitro susceptibility of lactobacilli to classes of 
antibiotics, and the effects of antibiotic use for any indication on colonization of the vagina and 
rectum by lactobacilli and its association with vulvovaginal candidiasis. 
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2.0 LITERATURE REVIEW 
 
 
2.1 ANTIBIOTIC CONSUMPTION 
 
2.1.1 Regional variations in antibiotic consumption 
 
Antibiotics are one of the most commonly prescribed classes of medications. Antimicrobial use 
varies by country, regions within countries, and classes of antibiotics. A study that compared the 
outpatient antibiotic consumption in the United States to that of 27 European countries in 2004 
reported that the US ranked fourth behind Greece, France, and Italy. The antibiotic use data was 
based on reimbursement, distribution, or sales data. The defined daily dose per 1000 inhabitants 
per day (DID) for Greece, France, Italy, and the US was 33.38, 27.09, 25.69,  and 24.92, 
respectively, while the Netherlands had the lowest antibiotic consumption at 10.00 D ID. The 
overall consumption in the 27 European countries included in this study was 19.04 DID. Since 
the amount of antibiotic use was based on different data sources in each country, there may be 
issues with the estimates. Antibiotic consumption in Greece may have been overestimated since 
sales data was used which includes antibiotics that were exported to other countries.  Conversely, 
antibiotic use may have been underestimated in the US since it was based on retail data and did 
not include antibiotics dispensed from government and integrated healthcare pharmacies 
although the authors believe the latter had little impact on the antibiotic use estimates.52 
 While the US and Europe have recently improved methods to monitor antibiotic use in 
response to the increasing public health threat of antibiotic resistant microorganisms, antibiotic 
consumption surveillance is limited in resource-limited countries. Sales of carbapenems, which 
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are expensive, are 2 to 3 times higher in India, Pakistan, and Egypt than in the US.59 A study of 
25 hospitals in the Mediterranean region which included the countries of Cyprus, Egypt, Jordan, 
Lebanon, Malta, Tunisia and Turkey, found that the median defined daily dose (DDD) per 100 
bed days was 112 during 2004-2005.60 In contrast, the median DDD per 100 bed days was 592.0 
in 2011 in an academic teaching hospital in South Africa.61 These data suggest that there is a 
great deal of variation in antibiotic consumption between countries world-wide. 
 There are regional variations in antibiotic consumption within the US. While, the national 
average antibiotic prescribing rate, based on nu mber of prescriptions filled, was 801 per 1000 
persons during 2010, rates tended to be higher in the southern states and lower in the western 
states. The states with the highest antibiotic prescribing rates were Kentucky (1,196 per 100 
persons), West Virginia (1,177 per 100  persons), Tennessee (1,159 per 100 persons), and 
Missouri (1,136 per 100 persons), while the states with the lowest antibiotic prescribing rates 
were Alaska (510 per 100 persons), Hawaii (543 per 100 persons, California (554 per 100 
persons), and Oregon (556 per 100 persons). The antibiotic prescribing rate in Pennsylvania was 
slightly lower than the national average (787 per 1000 persons).49 
 
2.1.2 Distribution of antibiotic classes consumed 
 
While the most commonly prescribed classes of antibiotics varies by country, penicillins are the 
most common in the US and Europe.49, 52 In 2010, 31% of the antibiotics dispensed in the US 
were penicillins, followed by macrolides (27%), cephalosporins (14%), fluoroquinolones (12%), 
and tetracyclines (8%).49 While penicillins were also the most commonly used antibiotics in 27 
European countries based on 2004 estimates, the relative amounts of other antibiotic classes 
varied between countries. In some countries such as Greece, Italy, Hungary, Denmark, and 
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Austria, fluoroquinolones were the second most common class of antibiotic, followed by 
cephalosporins, and then macrolides. Cephalospronis were more commonly used than macrolides 
and fluoroquinolones in Belgium, Croatia, Luxembourg, and Israel.52 
 
2.1.3 Indications for antibiotic use 
 
The conditions for which antibiotics are prescribed vary in relative frequency depending on the 
population served and clinical setting.  In studies that have evaluated ambulatory and outpatient 
care settings, nursing homes, and women before and during pregnancy, antibiotics were most 
often used to treat upper respiratory illnesses, followed by genitourinary conditions, skin and soft 
tissue infections, and digestive conditions.10, 58, 62-63 In children, the most common indication for 
antibiotic use is otitis media which is usually preceded by an upper respiratory infection.54 
 Upper respiratory infections are a m ajor target in national campaigns efforts to reduce 
unjustified antibiotic use since studies indicate a high prevalence for over-prescribing antibiotics 
for these conditions.  A study that evaluated an average of 985 million ambulatory visits per year 
among adults in the US from 2007-2009, found that antibiotics were prescribed during 101 
million (10%) of these visits annually. Antibiotics were most commonly prescribed for 
respiratory conditions (41% of antibiotics). While antibiotics were prescribed during 65% of 
respiratory conditions for which antibiotics were potentially indicated, they were also prescribed 
during 46% of visits for respiratory conditions for which antibiotics were rarely indicated.10 
Another study that evaluated ambulatory care national survey data from 2006 to 2010 reported 
similar results. There were 69 million visits in which there was a diagnosis of rhinosinusitis. 
Antibiotics are not recommended for uncomplicated cases of acute rhinosinusitis, and 
confirmatory diagnostic tests are recommended before prescribing antibiotics for chronic cases. 
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However, antibiotics were prescribed in 85.5% of acute rhinosinusitis cases and 69.3% of 
chronic rhinosinusitis cases in this study.62 
 
2.1.4 Antibiotic use in women 
 
Few studies have specifically evaluated antibiotic consumption in women. A study of antibiotic 
prescribing patterns in general practices in the United Kingdom, reported that 39% of all 
females, including children, were prescribed an antibiotic in 1996 for an overall rate of 852 per 
1000 patient years, while 29% of males were prescribed an antibiotic for a rate of 607 per 1000 
patient years.  However the antibiotic prescribing rates in reproductive-aged women (16-34 years 
and 35-54 years) were nearly twice as high as the rate in men in the same age groups (850 
versus 473 pe r 1000 pa tient years and 739 ve rsus 405 pe r 1000 pa tient years, respectively).54 
Two European studies that compared antibiotic use during pregnancy with the year prior to 
pregnancy found that overall antibiotic prescribing was slightly higher during the non-pregnant 
period.57, 58 One of these studies evaluated 115,000 women who had a live birth between 1992 
and 2007 i n the United Kingdom. The authors reported that antibiotic prescriptions per 1000 
women for respiratory and urinary tract infections in the year prior to pregnancy were 269 and 93 
respectively. While the antibiotic prescribing rate during pregnancy was similar to the pre-
pregnant rate for respiratory infections (228 per 1000 women), the prescribing rate for urinary 
tract infections nearly doubled (164 per 1000 women). The antibiotic prescribing rate without a 
reported indication was around 400 per 1000 women both before and during pregnancy.58 The 
results of these studies indicate that antibiotic consumption is higher in reproductive-aged 
women than in men, and that the indications for use and subsequently the classes of antibiotics 
prescribed change during pregnancy.  
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 Antibiotic stewardship programs have explored several methods to reduce unjustified 
antibiotic use including patient and prescriber education, clinical decision support strategies in 
the form of treatment algorithms, prospective audit and feedback, and formulary restrictions.64 
However, these programs have had mixed results and the world-wide prevalence of antibiotic use 
remains high. The use of antibiotics in commercial agriculture further increases the global 
antibiotic burden. The current literature is lacking in the epidemiology of antibiotic use in non-
pregnant reproductive-aged women, particularly in the US which has one of the highest 
antibiotic consumption rates. Sexually active women are at risk for acquiring an infection by 
antibiotic resistant bacteria, particularly drug-resistant N. gonorrhoeae which is classified as an 
urgent public health threat in the United States.3 Studies on antibiotic prescribing patterns in non-
pregnant women are needed in order to understand the burden of antibiotic use in this population 
and their potential for adversely affecting the indigenous vaginal microflora and subsequently 
increasing the risk for acquiring vaginal infections. 
 
2.2 ANTIBIOTIC SUSCEPTIBILITY OF VAGINAL LACTOBACILLI 
 
2.2.1 Antibiotic susceptibility of vaginal lactobacilli in vitro 
 
Lactobacilli are gram positive rods that can range from microaerophilic to strictly anaerobic. All 
Lactobacillus species produce lactic acid and most strains of some species, like L. crispatus and 
L. jensenii, produce hydrogen peroxide. The principal mode of action for many classes of 
antibiotics is the disruption of bacterial cell wall synthesis.  Like most facultative gram positive 
bacteria, nearly all isolates of lactobacilli are susceptible to penicillins, cephalosporins, 
macrolides, clindamycin, and tetracycline (80-100%) and all are resistant to metronidazole and 
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fluoroquinolones.65-69 There is also evidence that antibiotic susceptibility patterns vary between 
Lactobacillus species.67-68, 70-71 
 The primary species of Lactobacillus that colonize the vagina and rectum are L. 
crispatus, L. jensenii, L. gasseri, and L. iners.72, 73  Women colonized by L. crispatus in the 
vagina have reduced incidence of bacterial vaginosis while women colonized by L. gasseri 
and/or L. iners are at higher risk of shifting to an abnormal microflora, which is the precursor to 
developing bacterial vaginosis.15, 73-74 While most of the studies of in vitro antibiotic 
susceptibility testing have focused on the Lactobacillus species that are involved in food 
production, there are four published studies which reported results for isolates/species recovered 
from the genital tract.65-68 
 A Korean study evaluated the susceptibility of 108 vaginal Lactobacillus isolates from 
healthy women to 13 antimicrobial agents using the broth dilution method described by Clinical 
and Laboratory Standards Institute (CLSI). The majority of the isolates (76%) were identified as 
L. crispatus or L. acidophilus, 5% as L. gasseri, and 4% as L. jensenii. Using the CLSI 
interpretive breakpoints for anaerobes, all of the Lactobacillus isolates were susceptible to 
erythromycin and tetracycline, and 96% were susceptible to cefotaxime (3rd generation 
cephalosporin). All isolates were resistant to metronidazole. While the susceptibility of the 
Lactobacillus isolates to clindamycin was tested, the authors only reported the MIC90 for this 
antibiotic so it is not possible to determine the percentage of susceptible isolates. According to 
the published results, 8% of the Lactobacillus isolates were susceptible to penicillin and 49% 
were susceptible to ampicillin.65 The unusual high rate of resistance of Lactobacillus isolates to 
penicillins in this study was unexpected and was unique to this study. It is possible that the broth 
dilutions were contaminated when testing these antibiotics. 
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 A US study evaluated 36 strains of lactobacilli isolated from women who had normal 
vaginal flora. The Lactobacillus strains were not identified to the species level.  The sensitivity 
of the lactobacilli to 11 antibiotics was performed using the agar dilution method. Only the 
MIC50, MIC90, and the range were reported so it is not possible to determine how many were 
susceptible to each agent. However, the authors stated that all 36 isolates were resistant to 
ciprofloxacin (fluoroquinolone), and that ampicillin (penicillin) and cefuroxime (2nd generation 
cephalosporin) were highly active against lactobacilli. However, fewer than half of the isolates 
were sensitive to 5 other commonly used cephalosporins.66   
 A Finnish study of 85 cases of Lactobacillus bacteremia assessed antimicrobial 
susceptibility of the isolates using an agar diffusion method. The majority of clinical strains were 
identified as L. rhamnosus (n=46), L. fermentum (n=12), or L. casei (n=12). Nearly all of the 
clinical strains of Lactobacillus (95%) were susceptible to β-lactams, while susceptibility to 
cephalosporins varied by agent from 88% to cefuroxime to 35% to ceftriaxone. All of the isolates 
were susceptible to clindamycin, erythromycin, and doxycycline.67  
 Studies of clinical and probiotic Lactobacillus strains indicate that antimicrobial 
susceptibility patterns varies by species.67-68, 70-71 A recent study evaluated the species-specific 
antibiotic susceptibility of 150 vaginal and rectal Lactobacillus strains to 5 commonly used 
antibiotics using the anaerobic agar dilution method. The lactobacilli were identified to the 
species level as follows: L .crispatus (n=30), L. jensenii (n=30), L. gasseri (n=30), L. iners 
(n=30), L. vaginalis (n=9), L. coleohominis (n=9), L. fermentum (n=3), L. ruminis (n=3), L. 
rhamnosus (n=3), and L. johnsonii (n=3). While all lactobacilli tested were susceptible to 
cefazolin, there was species-specific heterogeneity in susceptibility to ampicillin, clindamycin, 
doxycycline, and azithromycin. Of 150 isolates, 125 (83%) were susceptible to ampicillin; L. 
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gasseri (100%), L. iners (90%), L. vaginalis (89%), L. jensenii (87%), L. crispatus (80%), L. 
coleohominis (67%), L. rhamnosus (33%), L. ruminis (0%), and L. johnsonii (0%).  While most 
isolates were susceptible to clindamycin (80%), all L. crispatus and L. jensenii, 87% of L. iners, 
and only 13% of L. gasseri strains tested were susceptible to this agent.  While the overall 
susceptibility to doxycycline was 83%, only 53% of L. iners, 67% of L. jensenii were susceptible 
to this antibiotic.  Only 53% of L. iners and 67% of L. rhamnosus were susceptible to 
azithromycin while all strains belonging to other species were susceptible. The results of this 
study show that 80% of L. crispatus isolates were susceptible to ampicillin and all were 
susceptible to cefazolin, azithromycin, tetracycline, and clindamycin. Conversely, 90% of L. 
iners isolates were resistant to 1 or more of 4 antibiotics tested.68 
 There is variability in the in vitro antibiotic susceptibility patterns between Lactobacillus 
species that colonize the genital tract. L. crispatus, the species associated with a healthy vaginal 
microenvironment is highly susceptible to commonly used antibiotics while L. iners, the species 
associated with abnormal microflora is resistant. 
 
2.2.2 Vaginal colonization by lactobacilli following antibiotic use 
 
Of 9 published studies which evaluated the association between antibiotic exposure and vaginal 
Lactobacillus colonization, four were observational cohort studies, one was a randomized 
clinical trial, and four were open-label, single group trials (Table 2.1). The studies evaluated a 
combined total of 1496 women, although one study accounted for two-thirds of this total. Two 
studies evaluated self-reported antibiotic use since last visit, while the remaining seven studies 
evaluated the following classes of antibiotics (two studies evaluated more than one antibiotic): 
penicillins (n=4), macrolides (n=2), fluoroquinolones (n=2), tetracyclines (n=2), and other (n=1) 
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which included clindamycin and metronidazole. For the nine studies, four reported no change in 
colonization in lactobacilli associated with antibiotic use (two penicillins, one fluoroquinolone, 
and one tetracycline) while the remaining 5 reported that antibiotic use was associated with loss 
of lactobacilli.14, 25-32 Only one study reported an increase in vaginal lactobacilli colonization in 
women who were on ampicillin therapy for the treatment of bacterial vaginosis.26 Thus, there is 
little consistency in the studies, which are described in more detail below. 
 
2.2.2.1 Vaginal colonization by lactobacilli following self-reported antibiotic use 
 
Two prospective observational cohort studies reported that recent self-reported antibiotic use was 
associated with decreased vaginal Lactobacillus colonization. A Kenyan study of 1020 H IV-1 
seronegative female sex workers evaluated the correlates of vaginal Lactobacillus colonization. 
Lactobacillus colonization status was assessed by culture at each bi-monthly visit and isolates 
were tested for hydrogen peroxide production. Women also reported during a face to face 
interview whether they had used antibiotics since their last visit and which type(s). Recent 
antibiotic use was defined as exposure to any antibiotic, excluding metronidazole, in the last 60 
days. At enrollment, 22% and 10% of women were colonized by any and hydrogen peroxide-
producing lactobacilli, respectively. Antibiotic use was reported at 7.2% of follow-up visits, 
while vaginal colonization by any lactobacilli and hydrogen peroxide-producing lactobacilli was 
detected at 19.0% and 8.2% of follow-up visits, respectively. Women who reported recent 
antibiotic use were 30% less likely to be vaginally colonized by any lactobacilli or by hydrogen 
peroxide-producing lactobacilli than women who denied antibiotic use, even after adjusting for 
demographic, behavioral, and medical factors. Additional factors that were independently 
associated with decreased colonization by hydrogen peroxide-producing lactobacilli included 
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older age, vaginal washing, Trichomonas vaginalis infection, and seropositivity for herpes 
simplex virus type 2. Women older than 40 were 50% less likely to be colonized by hydrogen 
peroxide-producing lactobacilli than younger women, and women who reported vaginal washing 
with soap and/or water were approximately 40% less likely to be colonized than those who did 
not. Concurrent Trichomonas vaginalis infection and seropositivity for herpes simplex virus type 
2 were associated with a 40% and 30% decrease in hydrogen peroxide-producing Lactobacillus 
colonization, respectively. Colonization by hydrogen peroxide-producing lactobacilli was 30% 
more common among women with concurrent vaginal candidiasis. The strengths of this study 
were the large sample size and that antibiotic exposure was categorized based on antibiotic 
classes. The authors reported a low isolation rate of Lactobacillus at enrollment which may have 
been due to the limited culture method used in the study or the characteristics of the population. 
Since this study included only Kenyan commercial sex workers who engage in risky sexual 
behaviors and are at risk for acquiring vaginal infections, the generalizability of the results to 
other populations of women is limited.14 
 A smaller cohort study evaluated factors associated with sustained colonization by 
vaginal Lactobacillus, in 101 women who attended adolescent and sexually transmitted disease 
clinics. Lactobacillus colonization status was detected by culture and isolated strains were tested 
for hydrogen peroxide production. Lactobacillus cultures and self-reported antibiotic use were 
obtained at enrollment and at 4- and 8-months of follow-up. Of the 101 women, 96 (95%) were 
colonized by lactobacilli at one or more visits and 60 (59%) were colonized at all 3 visits. Of the 
women who were colonized at each visit, 75% to 80% were colonized by hydrogen peroxide-
producing strains. Antibiotic exposure was reported at 7.2% of the nearly 8900 follow-up visits. 
Women who reported any antibiotic use in the last 4 months were more likely to lose 
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colonization by hydrogen peroxide-producing lactobacilli either by the first or second follow-up 
visit (38%) compared to women who did not use antibiotics (8%, p<0.001). The only other factor 
that was associated with loss of hydrogen peroxide-producing Lactobacillus colonization was 
self-reported weekly vaginal intercourse. Among 34 w omen who lost hydrogen peroxide-
producing Lactobacillus colonization, 68% reported having sexual intercourse at least once a 
week, while only 35% of 23 women with persistent hydrogen peroxide-producing Lactobacillus 
colonization reported weekly sexual intercourse. Race, age, contraceptive methods, or number of 
male sexual partners were not associated with Lactobacillus colonization in this study. The 
authors did not adjust for other potential explanatory factors in their analyses and less than half 
of the initial study cohort of 263 w omen was evaluated due to loss to follow-up and out of 
window visits which were weaknesses of this study. Furthermore, the prevalence of antibiotic 
use in the cohort was not reported. The strengths of this study were the quality of the methods 
used to isolate and identify Lactobacillus.25 
 
2.2.2.2 Vaginal colonization by lactobacilli following penicillin use 
 
Four studies evaluated the effect of penicillins on vaginal Lactobacillus colonization. A study of 
32 women, who were treated with ampicillin for 1 w eek, used aerobic and anaerobic culture 
media to detect Lactobacillus colonization and isolates were tested for hydrogen peroxide 
production.  There was a 7% increase from pre-treatment levels in the prevalence of colonization 
by hydrogen peroxide-producing strains at 1-week, followed by a 17% increase at the 1-month 
visit. This increase could be due to a r eduction in anaerobic bacteria since these women were 
being treated for bacterial vaginosis. Statistical analyses were not performed to determine 
whether the observed differences were significant.26 In contrast, a randomized clinical trial 
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evaluated the effect of a 5-day regimen of amoxicillin on vaginal Lactobacillus colonization 
among 15 healthy, non-pregnant women, all of whom had normal Lactobacillus flora, as 
determined by a vaginal smear classification system, prior to initiation of therapy. There was a 
statistically significant reduction in the number of lactobacilli throughout the treatment period 
among 70% of the women. However, at the 1-week post-treatment visit, only 27% of women 
showed a reduction and all of the women, once again, had normal Lactobacillus flora by the 2-
week post-treatment visit. A limitation of this study was that the reduction in Lactobacillus 
colonization was assessed by vaginal smear which is a semi-quantitative method based on Gram 
stain morphology rather than culture methods. This method is not specific to lactobacilli since 
other species of bacteria have similar Gram stain morphology and it does not mean that the 
organisms were viable.27 
 The remaining two small pilot clinical trials which included healthy women who had no 
exposure to antibiotics 2 to 3 months prior to enrollment, found no change in the number of 
vaginal lactobacilli before and after treatment with pivmecillinam for 7 days (N=20) or 
phenoxymethyl-penicillin for 10 days (N=6). While both these studies detected Lactobacillus 
colonization using aerobic and anaerobic cultures on selective and non-selective culture media, 
neither of these studies performed statistical analyses. 28 ,29 In addition, the strict inclusion criteria 
used in the phenoxymethyl-penicillin study may have been selective for women who were less 
likely to lose Lactobacillus colonization since they had to maintain normal flora throughout two 
menstrual cycles. This resulted in the exclusion of 8 of  the 14 women initially enrolled in the 
study.28 
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2.2.2.3 Vaginal colonization by lactobacilli following macrolide use 
 
Two studies evaluated the association between macrolide use and vaginal colonization by 
lactobacilli. A study that included 17 women treated with a single dose of azithromycin for 
cervicitis or a chlamydial infection, reported that while there was a 6% increase in the proportion 
of women colonized by any lactobacilli between the pre-treatment and 1-month post-treatment 
visits, the proportion of women colonized by hydrogen peroxide-producing strains decreased by 
6%.26 A smaller study evaluated the effects of a 7-day or 10-day regimen of clarithromycin on 
vaginal flora in 12 women being treated for sinusitis or bronchitis. In contrast to the results 
reported by Agnew et al, this study found that 4 (33%) women were colonized by lactobacilli 
before treatment and none were colonized at 4-6 weeks post-treatment. While it was stated that 
this difference was statistically significant (P<0.025), this result could not be duplicated using 
either an unpaired or more appropriate paired statistical test.30 
 
2.2.2.4 Vaginal colonization by lactobacilli following fluoroquinolone use  
 
Two studies evaluated the effect of prulifloxacin, a fluoroquinolone, on the vaginal Lactobacillus 
microflora. Tempera et al evaluated the effect of a 5 -day regimen among 15 healthy, non-
pregnant women. All of the women had normal Lactobacillus flora, as determined by a vaginal 
smear, prior to therapy and at all follow-up visits.27 Another study that evaluated vaginal 
Lactobacillus colonization in 51 women who underwent a 14-day course of prulifloxacin therapy 
for symptomatic urinary tract infection found similar results. Of the 41women with baseline 
colonization, 38 ( 93%) maintained colonization at the 6-month post-treatment visit (P=0.9). 
While a vaginal swab sample for microbial evaluation was also collected at the 1- and 3-month 
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visits, these results were not reported and would have been more indicative of the effect of 
prulifloxacin on vaginal lactobacilli.31 
 
2.2.2.5 Vaginal colonization by lactobacilli following tetracycline use 
 
The association between doxycycline use and vaginal Lactobacillus colonization has been 
evaluated in two studies. A clinical trial assessed the effect of a 5-day course of doxycycline on 
vaginal microbes in 91 women undergoing in vitro fertilization. There was no difference in the 
proportion of women with hydrogen peroxide-producing lactobacilli before (30%) and 2-5 days 
after starting doxycycline therapy (31%). While it was stated that these differences were not 
statistically significant, the investigators did not perform a paired analysis which would have 
been more appropriate for these data.32 The second study evaluated the effect of a 7-day course 
of doxycycline on vaginal lactobacilli in 43 women being treated for cervicitis or a chlamydial 
infection. While there was a 9% to 11% decrease in the proportion of women colonized by any 
and hydrogen peroxide-producing lactobacilli at the 1-week visit, the proportion of colonized 
women returned to pre-treatment levels by the 1-month visit.26  
 
2.2.2.6 Vaginal colonization by lactobacilli following metronidazole and clindamycin use 
 
The effect of intravaginal clindamycin and metronidazole therapy on vaginal Lactobacillus 
colonization was evaluated in one of the studies included in the present review. Of 73 women 
being treated for bacterial vaginosis, 28 used vaginal clindamycin cream for 7 days, and 45 used 
vaginal or oral metronidazole formulations for 5 days and 7 da ys, respectively. Of the women 
who were treated with clindamycin, 50% were colonized by any Lactobacillus at baseline and 
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29% were colonized by hydrogen peroxide-producing strains. While these proportions decreased 
to 25% and 11%, respectively, 1-week after initiation of therapy, there was a marked increase by 
the 1-month visit where 87% of women were colonized by any and 57% were colonized by 
hydrogen peroxide-producing Lactobacillus. Women who were treated with metronidazole 
experienced a faster restoration of normal vaginal microflora. The proportion of women 
colonized by any Lactobacillus increased from 51% at baseline to 82% by 1-week and 93% by 1-
month post-treatment. While only 5 women were colonized by hydrogen peroxide-producing 
strains at baseline, more than half were colonized at the 1-week and 1-month visits. The large 
increases in vaginal Lactobacillus colonization observed in women who used clindamycin and 
metronidazole for the treatment of bacterial vaginosis was likely related to a reduction of 
anaerobic bacteria which enhances subsequent colonization by lactobacilli.26 
 From the results of the nine studies included in this review, there is some evidence of an 
association between antibiotic use and vaginal Lactobacillus colonization. Recent self-reported 
antibiotic use was associated with reduced vaginal Lactobacillus colonization.14, 25 This finding 
was consistent in both studies in which it was evaluated and is perhaps the strongest evidence 
that antibiotic use may affect Lactobacillus colonization in the vagina since these studies 
accounted for 75% of the combined total of women in the studies included in this review, the 
studies were longitudinal so temporality between antibiotic exposure and reduction in 
Lactobacillus colonization was established, and the conclusions were verified using appropriate 
statistical analyses. However, both studies included women at high risk for acquiring vaginal 
infections and subsequently antibiotic exposure so the results may not be generalizable to other 
populations of women. The larger of the two studies reported a 30% reduction in vaginal 
Lactobacillus colonization following antibiotic use. This was an important finding since this 
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cohort, comprised of Kenyan female sex workers, had a low prevalence of vaginal Lactobacillus 
colonization (22%) at enrollment.14 This, in addition to their occupation, puts them at high risk of 
acquiring vaginal infections, including HIV.18, 19 Therefore, a reduction in vaginal colonization 
by lactobacilli, particularly by hydrogen peroxide-producing strains, could have a significant 
public health impact.  
 Even though penicillins and tetracyclines have an inhibitory effect on lactobacilli in vitro, 
the results of 5 studies indicated that penicillin and tetracycline use did not have any or at least a 
long-term effect on vaginal lactobacilli. Since these studies only included a combined total of 
207 women, larger studies are needed to verify these results.26-29, 32 Both studies which evaluated 
macrolides reported a slight decrease in hydrogen peroxide-producing strains of lactobacilli 
which was expected since macrolides inhibit gram-positive organisms in vitro.26, 30 There was no 
association observed between vaginal Lactobacillus colonization and the use of fluoroquinolones 
which was also expected since lactobacilli are resistant to this class of antibiotics. Antibiotics 
used to treat bacterial vaginosis, regardless of known in vitro activity against lactobacilli, 
resulted in increased colonization by lactobacilli in the vagina.26 These results are consistent with 
those reported in other studies .23, 24   
 Self-reported antibiotic use appears to impact lactobacilli which colonize the vagina. 
While this definition of antibiotic use included most classes of antibiotics, it is reflective of the 
level and variety of antibiotic exposure experienced by reproductive-aged women outside of a 
controlled clinical setting. The studies which prospectively assessed the effects of specific 
antibiotics on vaginal Lactobacillus colonization varied by antibiotic class and many had small 
sample sizes, employed vaginal smears, a suboptimal method of detecting Lactobacillus 
colonization so it is not known whether there was an effect on vi able organisms, or did not 
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provide adequate statistical analyses to support the conclusions. There is a need for larger, better 
designed studies to verify the apparent lack of association between use of specific antibiotic 
classes and vaginal Lactobacillus colonization that was observed in these studies. Furthermore, 
this review failed to identify any studies that evaluated the association between antibiotic use and 
rectal Lactobacillus colonization. Since the rectum is considered a reservoir for many species of 
bacteria which colonize the vagina, it would be important to determine whether antibiotic use 
affects Lactobacillus colonization at this site.17, 75 
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Table 2.1 Summary of studies evaluating the association between vaginal Lactobacillus colonization and antibiotic use 
 
Author Study 
Design 
Antibiotic Class: 
Antibiotic(s) Evaluated/ Duration 
Sample Size/ Population 
 
Results relating Lactobacillus colonization to antibiotic use 
Baeten 
(2009)
14
 
Prospective 
cohort 
Self-reported use: 
Any antibiotic use, excluding 
metronidazole, last 60 days 
Penicillin: NA 
Macrolide: NA 
Fluoroquinolone: NA 
Tetracycline: NA 
Other: NA 
N=1020 women (Kenyan) 
-18-45 years 
-HIV-seronegative sex worker 
Recent antibiotic use: Reduced Lactobacillus colonization by 30% 
 
Strengths: Large sample size, antibiotic exposure categorized by 
class, Lactobacillus colonization assessed by culture 
 
Limitations: Cohort homogenous with respect to demographics and 
high risk sexual behaviors which limit generalizability 
Vallor 
(2001)
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Prospective 
cohort 
Self-reported use: 
Any antibiotic use last 4 months 
 
Penicillin: NA 
Macrolide: NA 
Fluoroquinolone: NA 
Tetracycline: NA 
Other: NA 
N=101 women 
-14-44 years 
-Attending adolescent and STD 
clinics 
Recent antibiotic use: Women more likely to lose colonization by 
hydrogen peroxide-producing lactobacilli 
 
Strengths: Large sample size, Lactobacillus colonization assessed 
by culture 
Limitations: More than half of initial cohort lost-to-follow-up, 
analyses not adjusted for potential confounding variables, 
prevalence of antibiotic exposure not reported 
Agnew 
(1995)
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Prospective 
cohort 
Self-reported use: NA 
 
Penicillin: Ampicillin, 7 days 
 
Macrolide: Azithromycin, 1 day 
 
Fluoroquinolone: NA 
 
Tetracycline: Doxycycline, 7 days 
 
Other: Clindamycin, 7 days 
Metronidazole, 5-7 days 
N=165 women with 
vaginitis/cervicitis 
-18-45 years 
-Non-pregnant 
-No antibiotics <2 weeks 
Ampicillin: 
-Increase in hydrogen peroxide-producing Lactobacillus at 1 week 
-Increased colonization at 1-month visit  
Azithromycin: 
-Increase in any Lactobacillus at 1 month 
-Decrease in hydrogen peroxide producing Lactobacillus 
Doxycycline: 
-Decrease in hydrogen peroxide-producing lactobacilli at 1 week 
-Return to pre-treatment levels by 1-month 
Clindamycin: 
-Decrease in Lactobacillus colonization at 1-week 
-Increase above pre-treatment levels at 1-month  
Metronidazole: Increase in Lactobacillus colonization 
Strengths: Several classes of antibiotics evaluated, Lactobacillus 
colonization assessed by culture 
Limitations: Small sample size within antibiotic class, statistical 
analyses not performed 
Tempera 
(2009)
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Open-label 
randomized 
repeated 
dose study 
Self-reported use: NA 
Penicillin: Amoxicillin, 5 days 
Macrolide: NA 
Fluoroquinolone: Prulifloxacin, 5 days 
 
Tetracycline: NA 
Other: NA 
N=30 women 
-18-45 years 
-Non-pregnant 
-Normal menses 
-Normal vaginal flora 
-No antibiotic use <8 weeks 
Prulifloxacin: No change in Lactobacillus colonization 
 
Amoxicillin: Decrease in Lactobacillus colonization 
 
Strengths: Randomized study design 
Limitations: Small sample size, Lactobacillus colonization assessed 
by vaginal smear 
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Table 2.1 (continued) 
Sullivan 
(2005)
28
 
Prospective 
open-label 
pilot trial 
Self-reported use: NA 
 
Penicillin: Pivmecillinam, 7 days 
 
Macrolide: NA 
Fluoroquinolone: NA 
Tetracycline: NA 
Other: NA 
N=20 women 
-24-40 years 
-Normal menses 
-No antibiotics <3 months 
Pivmecillinam: No change in hydrogen peroxide-producing 
Lactobacillus at all visits 
 
Strengths: Lactobacillus colonization assessed by culture 
Limitations: Small sample size, statistical analyses not performed 
Sjöberg 
(1992)
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Prospective 
open-label 
pilot trial 
Self-reported use: NA 
 
Penicillin: 
Phenoxymethyl-penicillin, 10 days 
 
Macrolide: NA 
Fluoroquinolone: NA 
Tetracycline: NA 
Other: NA 
N=6 women 
-Not using contraceptives 
-Normal vaginal flora for 2 
menstrual cycles 
Phenoxymethyl-penicillin: 
-No change in lactobacilli in 5 of 6 women 
-One woman lost colonization 
 
Strengths: Lactobacillus colonization assessed by culture 
 
Limitations: Small sample size, statistical analyses not performed, 
selective inclusion criteria 
Kurowski 
(2000)
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Prospective 
cohort 
Self-reported use: NA 
Penicillin: NA 
 
Macrolide: Clarithromycin, 7-10 days 
 
Fluoroquinolone: NA 
Tetracycline: NA 
Other: NA 
 
N=12 women 
-18-55 years 
-Diagnosis of sinusitis or 
bronchitis 
-No conditions that affect vaginal 
flora 
Clarithromycin: Decrease in Lactobacillus colonization 
 
Strengths: Lactobacillus colonization assessed by culture 
 
Limitations: Small sample size, statistical analyses may have 
been improperly performed 
Cai T 
(2009)
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Prospective 
open-label 
pilot trial 
Self-reported use: NA 
Penicillin: NA 
Macrolide: NA 
 
Fluoroquinolone: Prulifloxacin, 14 days 
Tetracycline: NA 
Other: NA 
N=51 women 
-18-45 years 
-Symptomatic UTI 
-History of recurrent UTI 
-Non-pregnant 
-Negative for sexually transmitted 
infections 
Prulifloxacin: No change in Lactobacillus colonization 
 
Strengths: Lactobacillus colonization assessed by culture 
 
Limitations: Small sample size, 1- and 3-month post-treatment 
results not presented 
Moore 
(2000)
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Prospective 
clinical trial 
Self-reported use: NA 
Penicillin: NA 
Macrolide: NA 
Fluoroquinolone: NA 
 
Tetracycline: Doxycycline, 5 days 
 
Other: NA 
N=91 women 
-21-45 years 
-Undergoing in vitro fertilization 
 
Doxycycline: No change in hydrogen peroxide-producing 
Lactobacillus 
 
Strengths: Lactobacillus colonization assessed by culture 
 
Limitations: Paired statistical analyses not performed 
NA, not assessed 
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2.3 ASSOCIATION OF ANTIBIOTIC USE WITH VULVOAGINAL CANDIDIASIS 
 
Of 9 studies published within the last twenty years which evaluated the association between 
antibiotic exposure and vulvovaginal candidiasis (VVC) in non-pregnant women, two were 
prospective cohort studies, four were case-control studies, two were cross-sectional, and one was 
a randomized clinical trial (Table 2.2). Eight studies evaluated antibiotic use as a dichotomous 
variable, four of these included some analysis of antibiotic use by class, and one only evaluated 
metronidazole. For the nine studies, four reported a statistically significant positive association 
between antibiotic use and VVC, while the remaining five found no significant association.36-44 
These studies are described in more detail below. 
 Three prospective and one retrospective studies reported an association between 
antibiotic use and increased VVC.40-43 A randomized clinical trial evaluated incident VVC within 
28 weeks of follow-up among women who received 10 days of metronidazole therapy for 
treatment of bacterial vaginosis. Of the 112 women whose bacterial vaginosis had resolved after 
the initial antibiotic regimen, half were randomized to a suppression regimen of metronidazole 
administered twice weekly and half to placebo. Women with history of recurrent gynecological 
infection, including VVC, were excluded. Since it was a secondary outcome, the diagnostic 
criteria for VVC were not described.  The incidence of VVC was twice as high among women in 
the metronidazole group (43.1%) than among women in the placebo group (20.5%) which was a 
statistically significant difference. No other antibiotics were evaluated in this study.40 The major 
strength of this study was women were randomized to the exposure of interest and the antibiotic 
regimen was uniform.  The limitations of this study were the lack of adjustment for other 
possible risk factors variables and the lack of generalizability of results since all women initially 
had bacterial vaginosis and had resolution of symptoms prior to randomization.  
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 A small prospective matched cohort study evaluated incident symptomatic VVC, 
determined by clinical examination and diagnostic tests, and prevalence of positive vaginal 
Candida cultures in 44 women who were prescribed at least a 3-day course of antibiotics for a 
non-gynecologic diagnosis and 36 age-matched women with non-infectious conditions who did 
not receive antibiotics. The outcomes were evaluated at 1-2 weeks and 4-6 weeks. None of the 
women who did not receive antibiotics developed VVC and 11% had positive Candida cultures 
at follow-up while 22% and 37% of women who received antibiotics were positive for these 
outcomes, respectively. After adjusting for baseline Candida colonization, race, smoking, and 
oral sex, any antibiotic use was associated with nearly a 5- and 8-fold increased risk of VVC or 
positive follow-up vaginal Candida culture. The prospective nature of this study and uniform 
duration of antibiotic exposure among women recruited were strengths of this study. However, 
not only was the initial sample size small, but there was a 33% attrition rate in this study so the 
risk associated with antibiotic use may have been overestimated.41 
 A large prospective cohort study evaluated the seven week incidence of VVC in 77,080 
women receiving prescriptions for one of six antibiotics or one of six antidepressants identified 
from a post-marketing surveillance database. Diagnosis of VVC was determined by reports 
submitted by general practitioners. Overall, the incidence of VVC was less than 1%, in both 
groups of women, which is less than that observed in the other studies included in this review.  
VVC was 4 times more likely to occur among women taking antibiotics than those taking 
antidepressants, after adjusting for age. The unadjusted relative risk for VVC did not vary 
between women taking fluoroquinolones, cephalosporins, or macrolides.42 In addition to the 
rather large sample size, another strength of the study was the lack of inclusion criteria other than 
receiving a prescription for one of the drugs included in the study so the results are likely 
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generalizable to other populations. A major limitation of this study was the extremely low 
incidence of VVC. It was likely that there was under-ascertainment of VVC since detection of 
events relied on clinicians submitting study reports and the diagnostic criteria likely varied 
between clinicians. 
 A large case-control study evaluated the association between prevalent symptomatic 
VVC and any and class-specific antibiotic use. This study included 684  women with 
symptomatic VVC, defined as presence of symptoms and positive Candida culture, and 901 
asymptomatic controls. The prevalence of antibiotic use in the prior month was 19% among 
women with VVC and 11% among the asymptomatic controls. While there was an adjusted 2-
fold increased risk of incident VVC among women reporting any antibiotic use within the prior 
month compared to women not using antibiotics, this association did not vary by specific classes 
of antibiotics (penicillins, cephalosporins, fluoroquinolones, or sulfonamides). Antibiotic use 
was also associated with an increased risk of a repeated episode of VVC. Using antibiotics for 
more than 3 days was also significantly associated with VVC while a shorter course of 
antibiotics was not which suggested a dose-response relationship between duration of antibiotic 
exposure and VVC. The use of hormonal contraception and intrauterine devices were also 
associated with a 2 -fold increased risk of VVC compared to women not using birth control. 
Sexual behaviors, including new sexual partner and frequency of vaginal intercourse, were not 
associated with VVC in this study. The strengths of this study included the large sample size, the 
diagnosis of VVC was based on symptoms and confirmed by culture, categorizing antibiotic use 
by class, and being able to establish a slight dose-response relationship. A limitation of this study 
was that the cases and controls were recruited from separate clinics so there may have been 
characteristics common to the cases that predisposed them to VVC.43 
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 Two studies that evaluated antibiotic use as a dichotomous variable and by specific 
classes found no association with VVC. A prospective cohort study followed 151 asymptomatic, 
HIV-seronegative sex workers in Kenya for 12 months. These women received an oral and 
intravaginal placebo study product at enrollment. Symptomatic and asymptomatic VVC, defined 
as detection of yeast by wet mount microscopy, was present at 10% of 1,570 visits. Antibiotic 
use was reported at 12% of visits among women both with and without VVC. There was also no 
association with VVC when antibiotic use was stratified by metronidazole and all other classes.  
This study also did not find an association between VVC and hormonal methods of contraception 
(oral contraceptives, depot medroxyprogesterone acetate, intrauterine devices, or injectables) or 
sexual behavior measured by new or numbers of sexual partners. Concurrent vaginal 
Lactobacillus colonization was associated with an adjusted 4-fold increased risk only among the 
subset of women without concurrent bacterial vaginosis.44 While the characteristics of the cohort 
included in this study limits the generalizability of the results to other populations, the strengths 
of this were the prospective cohort design and evaluation of class-specific antibiotic use. The 
second study compared 64 women with symptomatic VVC confirmed by positive Candida 
culture to two different control groups; 196 asymptomatic women attending a university health 
clinic and 431 respondents to a mailed survey. Overall or class-specific antibiotic use was not 
associated with VVC, although the prevalence of antibiotic use was not reported. Oral 
contraceptives, vaginal intercourse or number of sexual partners were also not associated with 
VVC in adjusted analyses. However, women who engaged in receptive oral sex 2 or more times 
in the last 2 weeks were 3 t imes more likely to have VVC compared to women denying oral 
sex.45 This study may have lacked statistical power to detect an association between antibiotic 
use, especially class-specific antibiotic use, due to the small number of cases. 
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 The three remaining studies included in this review found no association between any 
antibiotic use and VVC. A prospective cohort followed 316 women, who denied antibiotic use in 
the past 30 days and were asymptomatic at enrollment, for up to 4 years. VVC, defined as use of 
an antifungal, was reported by 46 (14.5%) women and there were 488 reported prescriptions of 
antibiotics. Overall, 29% of women who used an antibiotic also used an antifungal compared to 
19% antifungal use among women who did not use an antibiotic. This difference was not 
statistically different. The authors also found no association between VVC and time since 
antibiotic use.46 Limitations of this study were that VVC may have been over-ascertained since 
antifungal use was used as a s urrogate for a definitive diagnosis and the use of a rural clinic 
population limits the generalizability of results. 
 Two cross-sectional studies also reported no a ssociation between antibiotic use and 
prevalence of positive vaginal Candida cultures. One study that evaluated 774 women who 
presented to the clinic with a gynecological problem, reported a 24% prevalence of a positive 
Candida albicans culture. The prevalence of antibiotic use 15 t o 30 days prior to the vaginal 
culture was 6% among culture negative women and 13% among culture positive women. The 
effect of antibiotic use that was closer to the time of culture could not be evaluated since women 
were excluded if they had used an antibiotic in the past 14 days. There was also no association 
between the use of oral contraceptive pills or vaginal sexual intercourse and the presence of 
positive Candida cultures. However, women with concurrent vaginal Lactobacillus colonization 
were 80% more likely to have a positive Candida albicans culture.47 Using a positive Candida 
cultures as the outcome likely resulted in capturing both symptomatic and asymptomatic VVC 
since 10% of women are asymptomatically colonized by yeast in the vagina.35 The second study 
evaluated 219 sexually active adolescents, aged 12 to 22 years, who presented at a health clinic 
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for a gynecological examination. Antibiotic use was not associated with the prevalence of a 
positive Candida culture which was 42%. However, antibiotic use was defined as more than 3 
times in the past 2 years so temporal associations of antibiotic use with vaginal Candida were not 
assessed. Oral sex was associated with an increased prevalence of positive Candida culture in 
this population, however frequency of vaginal intercourse, number of sexual partners, and use of 
oral contraceptives were not.48 Limitations of this study were that both symptomatic and 
asymptomatic VVC were captured and the results are likely not generalizable to adult women. 
 While its etiology is complex and unknown, it is widely believed by clinicians and 
women that antibiotic use is a risk factor for developing VVC. However, the results of the nine 
studies included in this review that evaluated antibiotic use in non-pregnant women show there is 
very little evidence to support this view, and more than half of these studies found no association 
between antibiotic use and VVC. There was heterogeneity in these studies with respect to the 
definitions of the outcome and antibiotic use, study design, comparator groups, and adjustment 
for other possible risk factors. Studies that evaluated a positive vaginal Candida culture as the 
outcome captured both asymptomatic colonization and symptomatic VVC which may have 
influenced the magnitude of the association of antibiotic use on VVC. Large prospective studies 
with detailed information on antibiotic use by class and duration that is also proximal to the 
diagnosis of VVC may be able to better assess the association between antibiotic use and VVC. 
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Table 2.2 Characteristics of studies evaluating antibiotic use for vulvovaginal candidiasis in non-pregnant women 
 
Author Study Design Outcome/ Sample Size/ Population Risk Factors Evaluated Results 
Sobel 
(2006)
40
 
Randomized 
control trial 
VVC within 28 weeks 
N=112 women with resolved bacterial vaginosis 
after 10 days of metronidazole therapy 
-56 received metronidazole suppressive therapy 
-56 received placebo 
-Women with history of recurrent gynecological 
infection excluded 
Antibiotic use: 
-Metronidazole 
Incident VVC associated with metronidazole use: 43.1% in 
metronidazole arm, 20.5% in placebo arm 
 
Strengths: Randomized study design, uniform antibiotic regimen 
Limitations: No adjustment for other possible risk factors, limited 
generalizability of results 
Xu (2008)
41
 Prospective 
matched 
cohort 
Incident symptomatic VVC (by exam and diagnostic 
tests) within 4-6 weeks 
Prevalence of positive Candida culture at 1-2 weeks 
and 4-6 weeks 
N=80 women: 
-44 prescribed >3 days of systemic antibiotics for 
non-gynecological diagnosis 
-36 age-matched (+5 years) women with non-
infectious conditions who did not receive antibiotics 
-18-64 years 
-No antibiotics/antifungals in past 4 weeks 
Any antibiotic use VVC: antibiotic use adjusted odds ratio = 4.8 
 
Positive Candida culture: antibiotic use adjusted odds ratio = 7.8  
 
Strengths: Prospective study design, uniform duration of 
antibiotic exposure 
Limitations: Small sample size; high attrition rate (n=27 women) 
Wilton  
(2003)
42
 
Prospective 
cohort 
VVC within 7 weeks (by clinician report) 
N=77,080 women 
-31,588 treated with antibiotics 
-45,492 treated with antidepressants 
-Age >16 years 
Antibiotic use, any and 
class-specific 
Any antibiotic use; adjusted odds ratio = 3.9  
Relative risks were similar for cephalosporins, macrolide, and 
fluoroquinolones 
Strengths: Prospective study design, large sample size, 
generalizability of results  
Limitations: Unknown, possibly variable diagnostic criteria, 
possible under-ascertainment of VVC (incidence <1%)  
Spinillo 
(1998)
43
 
Case-control Prevalent symptomatic VVC (presence of symptoms 
and positive Candida culture) 
N=1585 women; 
-684 with symptomatic VVC 
-901 asymptomatic controls 
Antibiotic use, any and 
class-specific, duration 
 
Hormonal contraception 
Intrauterine device 
 
Sexual behavior 
Any antibiotic use, previous month: adjusted odds ratio = 1.75 
Class-specific, unadjusted odds ratio: 
-Penicillins =1.93; Cephalosporins =1.73; Fluoroquinolones 
=1.89 
-Sulfonamide = 2.34; Others = 1.31 (not significant) 
Duration of antibiotic use >3 days, unadjusted odds ratio = 1.97 
Duration of antibiotic use 1-3 days, unadjusted odds ratio = 1.50 
(not significant) 
Hormonal contraception: unadjusted odds ratio = 2.5 
Intrauterine device: unadjusted odds ratio = 2.2 
Sexual behaviors (new partner, frequency of vaginal intercourse) 
not associated 
Strengths: Large sample size, evaluation of class-specific 
antibiotic use; dose-response relationship 
Limitations: Cases and controls recruited from separate clinics- 
possible selection bias  
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Table 2.2 (continued) 
McClelland. 
(2009)
44
 
Prospective 
cohort 
Symptomatic and asymptomatic VVC (presence of 
yeast by wet mount microscopy) within 12 months 
N=151 women 
-Sex workers in Kenya 
-18-45 years 
-HIV seronegative 
-Asymptomatic 
-Received placebo oral and intravaginal study 
product 
Antibiotic use, 
metronidazole, all  
others 
 
Hormonal contraception 
 
Sexual behavior 
 
Concurrent vaginal 
Lactobacillus 
colonization 
Antibiotic use not associated 
Hormonal contraception (oral contraceptives, DMPA, intrauterine 
device, injectable) not associated 
Sexual behavior (number of partners, new partner) not associated 
Concurrent vaginal Lactobacillus colonization: adjusted odds 
ratio = 3.75 only among subset without concurrent bacterial 
vaginosis 
 
Strengths: Prospective study design, evaluation of class-specific 
antibiotic use 
Limitations: Cohort homogenous with respect to demographics 
and high risk sexual behaviors which limit generalizability 
Geiger 
(1995)
45
 
Case-control Symptomatic VVC (confirmed by positive Candida 
culture) 
N=691 women 
-64 cases 
-196 asymptomatic controls 
-431 respondents from mailed survey 
 
Antibiotic use, any and 
class specific 
 
Oral contraceptives 
 
Sexual behaviors 
Antibiotic use , any or class-specific, not associated 
Oral contraceptives not associated in adjusted analyses 
Receptive oral sex, >2 times in last 2 weeks: adjusted odds ratio 
=3.5 
Vaginal intercourse or number of sexual partners not associated 
 
Strengths: Evaluation of class-specific antibiotic use 
Limitations: Small number of cases 
Glover 
(2003)
46
 
Prospective 
cohort 
Incident VVC by use of an antifungal within 4 years 
N=316 women 
-Asymptomatic 
-No antibiotics past 30 days 
Any antibiotic use 
 
No association with VVC 
 
Strengths: Prospective study design 
Limitations: Diagnostic criteria – possible over-ascertainment of 
VVC; limited generalizability 
Eckert 
(1998)
47
 
Cross-
sectional 
Positive Candida albicans culture 
N=774 women 
-Age 16-50 years 
-Presenting with a gynecological problem 
-No antibiotics past 14 days 
Any antibiotic use 
 
Hormonal contraception 
 
Sexual behavior 
 
Concurrent vaginal 
Lactobacillus 
colonization 
Any antibiotic use, 15-30 days prior to culture, not associated in 
adjusted model 
Oral contraceptive pills not associated 
Vaginal sexual intercourse (>4 times/month) not associated in 
adjusted model 
Concurrent vaginal Lactobacillus colonization: unadjusted odds 
ratio = 1.8, adjusted odds ration not shown 
 
Strengths: Large sample size 
Limitations: Both symptomatic and asymptomatic VVC captured 
Rylander 
(2004)
48
 
Cross-
sectional 
Prevalence of positive Candida culture 
N=219 women 
-12-22 years 
-Sexually active 
-Presenting for genital examination 
Any antibiotic use 
 
Oral contraceptives 
 
Sexual behaviors 
No association with antibiotic use (>3 times in past 2 years), oral 
contraceptives, frequency of vaginal intercourse, number of 
sexual partners 
Oral sex: increased prevalence of positive Candida culture 
 
Limitations: Both symptomatic and asymptomatic VVC captured, 
unable to assess temporal associations; limited generalizability 
VVC, vulvovaginal candidiasis; DMPA, depot medroxyprogesterone acetate; HIV, human immunodeficiency virus
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2.4 SUMMARY 
 
Antibiotic use is widespread and inappropriate use remains a public health concern despite 
national campaign efforts promoting judicious and proper antibiotic prescribing practices. 
Furthermore, very little is known about the burden of antibiotic use among healthy, non-pregnant 
women. Antibiotics could impact beneficial members of the vaginal flora such as Lactobacillus 
and may affect colonization by potential pathogens like Candida spp. The impact of antibiotic 
usage could occur directly in the vaginal microenvironment or in the rectal reservoir.  To date, 
studies that evaluated the effect of antibiotic use on  colonization by Lactobacillus and 
developing vulvovaginal candidiasis have mostly included crude assessments of antibiotic use or 
evaluated a single antibiotic in a controlled study. These studies have also included selective 
populations ranging from healthy women to those presenting with genital infections to 
commercial sex workers. Thus, the generalizability of the results is limited. Studies have not 
been designed to evaluate the relationship between antibiotic use and rectal Lactobacillus 
colonization. Similarly, while there is ample evidence that the in vitro susceptibility of 
Lactobacillus to specific antibiotic classes varies by species, studies have not evaluated whether 
any association between antibiotic use and colonization by these organisms differs between 
species. Such studies could provide valuable information that can be used in guiding choices for 
antibiotic therapy or prophylaxis in target populations such as pregnant women, women at high 
risk for acquiring sexually transmitted infections or with a history of recurrent vulvovaginal 
candidiasis, immunocompromised adults, or the elderly.  
 The following analyses are derived from a longitudinal evaluation of overall antibiotic 
use and class-specific antibiotic use in young, sexually active women. The frequency, type, and 
indication for antimicrobial use in healthy, non-pregnant women are described along with 
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demographic and behavioral factors associated with increased antibiotic use. In addition, the 
associations of overall and class-specific antibiotic use with the prevalence of vaginal and rectal 
colonization by Lactobacillus and the incidence of vulvovaginal candidiasis are also presented. 
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3.0 SPECIFIC AIMS AND POWER ANALYSES 
 
 
This dissertation is composed of three manuscripts, each pertaining to systemic and/or intra-
vaginal antibiotic use in non-pregnant women. 
 
Specific Aim for Manuscript 1: 
Describe the rate of antimicrobial use in healthy, non-pregnant women, identify the classes of 
antibiotics used, indications for use, estimate the amount of possible inappropriate use by 
consulting current prescribing recommendations, and identify demographic and behavioral 
factors associated with antibiotic use. This paper will improve our knowledge as to the burden of 
and reasons for antibiotic use in reproductive-aged women that may be used to help tailor 
educational efforts to promote judicious use of antibiotics in this population. 
Hypothesis: There are no differences in women who use or do not use antibiotics. 
Alternative Hypothesis: There will be differences in race and sexual behaviors between women 
who do and do not use antibiotics. 
Power Analysis for Specific Aim 1: The marginal prevalence of antibiotic use in this cohort 
was 10.8%. Based on a Fisher’s exact test evaluated at the 2-sided 0.05 significance level, this 
study will have 80% power to detect at least a 75% difference in the prevalence of antibiotic use 
between women who do and do not have the exposure of interest. 
 
Specific Aim for Manuscript 2: Evaluate the association of any and class-specific antibiotic use 
on vaginal and rectal colonization by hydrogen peroxide-producing Lactobacillus spp. This 
manuscript will be the first to evaluate the association of antibiotic use on rectal colonization by 
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lactobacilli and could improve our knowledge as to whether the use of any or only specific 
classes of antibiotics disrupts vaginal Lactobacillus colonization.  
Hypothesis: There will be no difference in the prevalence of vaginal or rectal Lactobacillus 
colonization between women with recent antibiotic exposure and those who do not have recent 
antibiotic exposure. 
Alternative Hypothesis: Women exposed to some classes of antibiotics will have a lower 
prevalence of vaginal or rectal Lactobacillus colonization than women without recent antibiotic 
exposure. 
Power Analysis: Based on a Fisher’s exact test evaluated at the 2-sided 0.05 significance level, 
this study will have 85% power to detect at least a  20% difference in the prevalence of 
Lactobacillus colonization between women who do  and do not  use antibiotics, assuming the 
prevalence in the unexposed group is at least 0.6. 
 
Specific Aim for Manuscript 3: 
Evaluate the association between any and class-specific antibiotic use and acquisition of 
vulvovaginal candidiasis in healthy, non-pregnant women. This paper could improve our 
knowledge pertaining to the association of overall antibiotic use with increased incidence of 
vulvovaginal candidiasis and whether the association varies by antibiotic class. 
Hypothesis: Recent antibiotic use will not be associated with incident vulvovaginal candidiasis 
Alternative Hypothesis: Women who report recent antibiotic use will be more likely to develop 
vulvovaginal candidiasis 
Power Analysis: Based on previous studies40-43, women exposed to antibiotics have at least a 
75% increased risk of developing vulvovaginal candidiasis. This study will have 80% power to 
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detect at least a 60% difference in the risk of acquiring vulvovaginal candidiasis between women 
who do and do not  use antibiotics, based on a log-rank test for equality of survival curves 
evaluated at the 2-sided 0.05 significance level. 
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4.1 ABSTRACT 
 
Objective: Describe antibiotic use patterns and indications for use among healthy non-pregnant 
women, and evaluate factors associated with antibiotic use. 
Study Design: 650 women, aged 18-40 years, were followed bi-monthly for up to 18 months in a 
prospective cohort study conducted in Pittsburgh, PA, Augusta, GA, and Houston, TX. 
Behavioral and antimicrobial use information was collected by interview. Poisson regression 
analysis was used to evaluate risk factors for antibiotic use. Appropriate antibiotic use was 
assessed using CDC recommendations for treatment of upper respiratory infections (URI). 
Results: The antibiotic use rate was 81.2 per 100 woman-years (95% confidence interval (CI): 
75.4-87.5). Of the 699 episodes of antibiotic use, the most common classes of antibiotics were 
metronidazole (24.2%), penicillins (22.6%), and macrolides (15.2%); 32.5% were broad 
spectrum agents.  Treatment of genitourinary infections accounted for 48.5% of all antibiotic use, 
while URI accounted for 26.2%. Of the 183 antibiotic uses for URI, 104 (56.8%) were broad 
spectrum antibiotics. Bronchitis, rhinosinusitis, and non-specific URI accounted for 21.2% of the 
total and 40.5% of the broad spectrum antibiotic prescriptions. Older age and being white were 
associated with inappropriate antibiotic use. Factors independently associated with antibiotic use, 
excluding those used for the treatment of URIs, included black race, increasing number of sex 
partners, and reduced vaginal lactobacilli.  
Conclusion:  The high antibiotic use burden in this population of young women was likely 
appropriate for the primary indications of genitourinary infections. However, broad-spectrum 
agents were often selected to treat URI conditions for which antibiotics provide little therapeutic 
benefit.  
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4.2 INTRODUCTION 
 
Antibiotics are one of the most commonly prescribed classes of medications. Widespread 
antibiotic use in humans and in commercial agriculture has contributed to a new public health 
threat, the emergence of antibiotic resistant bacteria. The Centers for Disease Control and 
Prevention estimate that antibiotic resistant infections cause more than 2 million illnesses and 
23,000 deaths per year in the United States.3 Hence, promoting appropriate antibiotic use is a 
public health priority.9 Understanding antibiotic prescribing patterns can help direct educational 
efforts to reduce unjustified antibiotic use.       
 While antibiotic prescribing patterns have been frequently described in outpatient and 
inpatient hospital populations, children, and the elderly, there are few reports about antibiotic use 
specifically in reproductive-aged women.50, 52-55 A study of antibiotic prescribing patterns in 
general practices in the United Kingdom, reported that the overall antibiotic prescribing rate in 
females, including children, was 852 per 1000 patient years in 1996 which was higher than the 
rate in males (607 per 1000 patient years). However, the antibiotic prescribing rates in women 
16-34 years of age was nearly twice as high as the rate in men in the same age group.56 A study 
which evaluated 115,000 women who had a live birth between 1992 and 2007 i n the United 
Kingdom, reported that antibiotic prescriptions for respiratory and urinary tract infections in the 
year prior to pregnancy were 269 and 93 p er 1000 women, respectively. While the antibiotic 
prescribing rate for respiratory infections during pregnancy was similar to the pre-pregnant rate, 
the prescribing rate for urinary tract infections nearly doubled during pregnancy.58 The results of 
these studies indicate that antibiotic consumption is considerably higher in reproductive-aged 
women than in men of the same age, and that the indications for use and subsequently the classes 
of antibiotics prescribed change during pregnancy. 
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 The current literature is lacking in the epidemiology of antibiotic use in non-pregnant, 
reproductive-aged women, particularly in the US which has one of the highest antibiotic 
consumption rates.52 Sexually active women are at risk for acquiring an infection by antibiotic 
resistant bacteria such as drug resistant Neisseria gonorrhoeae, which is classified as an 
urgent public health threat in the US.1 Studies on antibiotic prescribing patterns in non-
pregnant women are needed in order to understand the burden of antibiotic use in this population 
and to help tailor educational efforts to promote judicious use of antibiotics in this population. 
 The primary objectives of this longitudinal study were to describe antibiotic use patterns 
in non-pregnant, reproductive-aged women and to describe the classes of antibiotics and the 
indications for which they were prescribed. Another objective was to evaluate demographic and 
behavioral risk factors for antibiotic use.  
 
4.3 METHODS 
 
4.3.1 Study population 
 
This is a secondary analysis of a randomized, clinical trial designed to evaluate the efficacy of a 
group B Streptococcus (GBS) serotype III polysaccharide-tetanus toxoid conjugated vaccine. 
Briefly, non-pregnant, sexually active women aged 18-40 years who were using effective birth 
control methods, denied antimicrobial and antifungal use in the past 7 days, and were GBS 
culture-negative both vaginally and rectally were recruited from primary care and family 
planning settings in Pittsburgh, PA, Augusta, GA, and Houston, TX. Participants (n=663) were 
randomized to receive a single dose of GBS type III- tetanus toxoid vaccine or a licensed vaccine 
containing tetanus and diphtheria toxoids adsorbed for adult use. The clinical trial was approved 
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by the institutional review boards of the participating institutions. All participants provided 
written informed consent. The trial enrollment occurred from July 2003 to August 2006, and all 
follow-up visits were completed by February 2008. 
 Vaginal swabs for culture detection of GBS and lactobacilli, a  vaginal smear, 
demographics, behavioral information, and use of systemic or intra-vaginal antimicrobials were 
collected by pelvic examination and interview administered by trained research personnel at 
enrollment, 1- and 2-months, and then bi-monthly for 18 months. Antibiotic use was categorized 
by antibiotic class. The following classes of antibiotics were classified as broad-spectrum agents: 
amoxicillin/clavulanate, second- and third-generation cephalosporins, macrolides, 
fluoroquinolones, and lincosamides. GBS and Lactobacillus were isolated and identified by 
methods that have been previously described.76 The vaginal smear was Gram-stained and 
evaluated for bacterial vaginosis according to the Nugent criteria.77 
 
4.3.2 Covariates 
 
Variables considered as potential explanatory factors included study site, study arm, race, age, 
education, and marital and employment status at enrollment. Other variables which could change 
over time and for which data was collected at each visit included number of male sexual 
partners, new sex partner, frequency of vaginal intercourse, receptive anal intercourse, douching, 
Nugent score, vaginal Lactobacillus and GBS colonization, and contraceptive methods. 
Contraceptives were categorized as none, non-barrier methods (spermicides, tubal ligations, or 
copper intrauterine devices), barrier methods (condoms, diaphragms, or cervical caps), hormonal 
methods (oral contraceptive tablets, intrauterine devices containing levonorgestrel, the vaginal 
ring, transdermal patches, or implants), and depot medroxyprogesterone acetate (DMPA). 
 4.3.3 Statistical analysis 
 
Statistical analyses were performed using Stata statistical software release 11.2 (Stata Corp., 
College Station, TX), and statistical tests were evaluated at the 0.05 two-sided significance level. 
All women who completed at least one follow-up visit (N=650) were included in the analyses. 
The antibiotic use rate represents the number of antibiotic prescriptions per 100 woman-years. A 
population averaged Poisson longitudinal regression model based on repeated visit measures per 
woman was used to evaluate risk factors for antibiotic use and estimate the population averaged 
incidence rate ratios (IRRs). The count of antibiotic prescriptions that were reported since the 
previous visit up to the current visit for a given woman was the Poisson outcome variable, and 
the length of time from the previous visit to the current visit was the offset term. An 
exchangeable working correlation matrix was specified and modified sandwich estimates of the 
variance were calculated.78 Multivariable models were developed using forward regression and 
variables were retained in the model if the P value from the Wald chi-squared test statistic was 
0.05 or less. The final model was also adjusted for age. Appropriate antibiotic use was assessed 
using CDC recommendations for treatment of upper respiratory infections (URI).79 A modified 
Poisson regression model with sandwich estimates of the variance was used to identify factors 
that were associated with receiving any antibiotic for the subset of URI for which the use of 
antibiotics was inappropriate (bronchitis, rhinosinusitus, and non-specific URI) and to estimate 
relative risks.80 Models were developed using the same aforementioned procedure. 
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4.4 RESULTS 
 
This analysis included 650 w omen who completed 5599 f ollow-up visits over 860.8 w oman-
years. Most women (60%) completed all 10 scheduled follow-up visits and 91% completed 5 or 
more visits; the median follow-up time was 1.5 years. Antimicrobial use was reported by 341 
(52.5%) women at least once and one or more new antibiotic prescriptions were reported at 599 
(10.7%) of the follow-up visits. Women reported using a total of 699 antibiotic prescriptions for 
an overall antibiotic use rate of 81.2 per 100 woman-years of follow-up (95% confidence interval 
(CI): 75.4-87.5). Prescriptions for more than one course of antibiotics was reported at 75 visits; 2 
courses at 52  visits, 3 at 21 visits, and 4 at 2  visits. Among the women who reported 
antimicrobial use, the median number of prescriptions was 2 (range: 1-9 prescriptions). The most 
commonly reported antibiotics used were metronidazole (24.2%), penicillins (22.6%), and 
macrolides (15.2%), followed by fluoroquinolones (8.7%),  cephalosporins (8.2%), sulfonamides 
(6.7%), and tetracyclines (6.0%). The name of the antibiotic used could not be verified for 30 
(4.3%) of the prescriptions reported (Table 4.1). Of the 699 prescriptions reported by women, 
227 (32.5%) were for broad spectrum antibiotics. 
 The indications for antibiotic use by classes of antibiotics are shown in Table 4.2. Almost 
half (48.5%) of antibiotics were used to treat genitourinary conditions in 188 women. Bacterial 
vaginosis accounted for 20.6% of all antibiotic use, while treatment of urinary tract infections 
accounted for 13.3%, and sexually transmitted infections, including trichomoniasis, chlamydia, 
and gonorrhea, accounted for 10.9% of all antibiotic use. Genitourinary infections accounted for 
nearly all of the metronidazole use (96.4%), 62.3% of the fluoroquinolone prescriptions, and 
53.5% of prescriptions for tetracyclines, sulfonamides, nitrofurantoin, lincosamides, 
aminoglycosides, and unknown antibiotics. About a third of cephalosporin (38.6%) and 
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macrolide (28.3%) prescriptions were also for genitourinary infections, primarily for the 
treatment of sexually transmitted infections. 
 Antibiotics were prescribed for 176 of the 380 (46.3%) upper respiratory infections that 
were reported to study personnel by 131 women and accounted for 26.2% of the antibiotics used. 
Two courses of antibiotics were prescribed for seven URIs for a total of 183 antibiotic uses and 
104 (56.8%) of those were broad spectrum antibiotics. Pharyngitis cases that were presumed to 
be due to group A streptococcal infection and pneumonia accounted for 19.1% of the URI 
antibiotic uses, bronchitis and rhinosinusitis for 53.0%, and the remaining 27.9% were non-
specific URI. Bronchitis, rhinosinusits, and non-specific URI accounted for 21.2% of the total 
and 40.5% of the broad spectrum antibiotic use. URI contributed to more than half of the 
exposure to macrolides (59.4%) and penicillins (51.3%) in this cohort of women. 
 There were 340 cases of bronchitis, rhinosinusitus, or non-specific URI reported by 229 
women and 143 (42.1%) of the cases among 106 women were treated with an antibiotic; among 
the antibiotics prescribed, 88 (60.5%) were broad-spectrum agents and 74 (50.0%) were β-
lactams (penicillins, cephalosposrins). Older age and being white were independently associated 
with receiving an antibiotic for bronchitis, rhinosinusitus, or non-specific URI, which was 
considered to be inappropriate antibiotic use (Table 4.3). White women were more likely to 
receive an antibiotic for these conditions than non-white women (adjusted relative risk (aRR) 
=1.51, 95% confidence interval (CI): 1.08-2.10), as were women 35-40 years of age compared to 
18-19 year olds (aRR=2.42, 95% CI: 1.05-5.57). 
 Following genitourinary infections and URIs, the next most common indications for 
antibiotic use were dental (9.6%) and skin conditions (8.0%). Antibiotic use for other indications 
(gastrointestinal, ear and eye infections, musculoskeletal, and others) was uncommon (7.7%). 
Dental indications, which included dental infections, abscesses, and prophylaxis for cleaning, 
extractions and surgery, accounted for 32.9% of the penicillin use. Most of the skin conditions 
were treated with cephalosporins (30.4%) or other classes of antibiotics (55%) which were 
primarily tetracyclines for the treatment of acne (Table 4.2). 
 The antibiotic use rate did not vary significantly by vaccine arm, employment and marital 
status, or methods of contraception. While the antibiotic use rates at the Pittsburgh and Houston 
study sites were similar (92.8 and 97.6 pe r 100 woman-years, respectively), the antibiotic use 
rate was significantly lower at the Augusta site, at 49.5 per 100 woman-years. Antibiotic use also 
varied significantly by categories of race, age, and education. Black women used more 
antibiotics than white women (94.3 versus 68.0 uses per 100 woman-years), as did women 
without any college education compared to women with at least 17 years of education (100.3 
versus 60.9 per 100 woman-years). Antibiotic use also varied across the age spectrum with the 
lowest rates in teens (58.4), increasing among women in their early twenties, peaking in 25-29 
year olds at 93.3, and then declining to 62.1 among women 35-40 years of age (Table 4.4). 
 Sexual activity was associated with antibiotic use. Women who reported a  new sexual 
partner since the last visit and those reporting multiple male partners used antibiotics more often 
than women who did not report a new partner or were sexually abstinent. Vaginal microflora at 
the prior visit was also associated with antibiotic use rates. Women with a Nugent score >4, 
which reflects reduced numbers of vaginal lactobacilli, had higher antibiotic use rates than those 
with a score that is consistent with a Lactobacillus-predominant vaginal microflora (Table 4.4). 
 Multivariable regression models to determine correlates of appropriate antibiotic use 
were constructed after excluding antibiotics used to treat URIs (Table 4.5). Race, number of sex 
partners, abnormal vaginal microflora (Nugent score 4-10) at the prior visit, and study site were 
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independently associated with antibiotic use. The adjusted incident rate ratio (aIRR) for black 
women was 1.48 (95% confidence interval (CI): 1.15-1.90) compared to white women. Women 
reporting one sex partner  had a 48% increased  aIRR (95% CI: 1.03-2.14) and those reporting 2 
or more partners a 2 -fold increase (aIRR=2.04, 95% CI: 1.19-3.50), as compared to sexually 
abstinent women. A Nugent score >4 at the prior visit was associated with a 80% increased aIRR 
(95% CI: 1.45-2.24). 
 Compared to women at the Pittsburgh site, women at the Augusta site had a decreased 
aIRR of 0.49 (95% confidence interval (CI): 0.36-0.66), while women at the Houston site did not 
have a s ignificantly decreased aIRR (Table 4.5). However, only 38.1% of women in Augusta 
were 25 years or older compared to 51.1% of women at the other two sites (p=0.003). Women in 
Augusta were also less likely to have a Nugent score >4 at their prior visit than women from the 
Pittsburgh and Houston sites (odds ratio=0.67, 95% CI: 0.51-0.87; p=0.003) and less likely to 
have multiple sex partners (p=0.050, data not shown). Since there were differences between the 
study sites in several factors associated with antibiotic use, site-specific analyses were 
performed. While number of sex partners and Nugent score >4 at the prior visit remained 
significantly associated with increased antibiotic use among women from Pittsburgh and 
Houston, black race was the only factor associated with antibiotic use for indications other than 
URI among women from Augusta.  
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4.5 DISCUSSION 
 
The overall antibiotic use rate in this population of non-pregnant, reproductive-aged women 
from 2003 to 2008 was 81.2 per 100 woman-years. This rate is similar to the national average of 
80.1 among all persons in the US in 2010.49 However, the antibiotic use rate for the Pittsburgh 
study site of reproductive-aged women was 92.8 per 100 woman-years which is higher than the 
rate for the entire state of Pennsylvania in 2010 (78.7). The antibiotic use rate for the Houston 
site was also higher than the Texas state average (97.6 versus 86.7). The rate for the Augusta 
site, however, was considerably lower than the Georgia state average (49.5 versus 85.2). The 
national and state-specific antibiotic prescribing rates were based on the entire population 
whereas the antibiotic use rates in this study were based on only reproductive-aged women, 
which likely accounts for the differences since previous studies have shown that the antibiotic 
prescribing rates in women were higher than those of men.56 Although antibiotic use was high in 
our study population, the rates observed were similar to those observed among women 16-34 
years of age in a population based study in Wales.56 The antibiotic use rate among women in 
Augusta was nearly half of the rate among women from Pittsburgh and Houston. However, this 
was likely due to differences in age, education, sexual activity, and Nugent score among women 
between the three study locations since these factors were also associated with antibiotic use in 
this study. 
 Metronidazole, penicillins, macrolides, fluoroquinolones, and cephalosporins were the 
five most commonly prescribed classes of antibiotics for the women in this study, which is 
similar to the antibiotic class distribution for the US in 2010 where the four most common 
antibiotics dispensed were penicillins, macrolides, cephalosporins, and fluoroquinolones.49 The 
primary difference in the distribution of antibiotics used was for metronidazole, the most 
47 
 
prescribed antibiotic in the present study. Metronidazole was prescribed primarily for the 
treatment of bacterial vaginosis, the most common genital tract infection in our population of 
adult women. URI is the most common indication for antibiotic use in other adult populations.10, 
62 
 In our study of young women, nearly half of the antibiotics were prescribed for 
genitourinary conditions, followed by URI, dental conditions or procedures, and skin conditions. 
In contrast, a study that evaluated women before and during their pregnancy, found that 
antibiotics were most often used to treat URIs, followed by genitourinary conditions. Antibiotics 
were also most often used to treat URIs, followed by genitourinary conditions, skin and soft 
tissue infections, and digestive conditions in studies that have evaluated adults in outpatient care 
settings and nursing homes.10, 58, 62, 63  
 Minimizing the inappropriate use of antibiotics is a public health priority.9 Upper 
respiratory infections are a major target in national campaigns efforts to reduce unjustified 
antibiotic use since studies indicate a h igh prevalence for over-prescribing antibiotics for these 
conditions.10, 62 Furthermore, the use of broad-spectrum antibiotics contributes to the 
development of antibiotic-resistant infections.81, 82 In the present study, while 46% of upper 
respiratory infections were treated with antibiotics, 57% were treated with broad spectrum 
antibiotics. The proportion of women receiving antibiotic therapy for URIs, including broad 
spectrum antibiotics, was similar to adults in outpatient settings.10, 83 In our study, URIs for 
which antibiotics are rarely indicated79 accounted for 21% of total antibiotic use and 40% of 
broad spectrum antibiotic use. White women were more likely to receive an antibiotic for 
bronchitis, rhinosinusits, and nonspecific URI, and the use increased with increasing age. These 
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findings are consistent with studies evaluating determinants of receiving a broad-spectrum versus 
a narrow-spectrum antibiotic for URI in adults.10, 84  
 After removing antibiotic use for treatment upper respiratory infections, predictors of 
antibiotic use were similar to the known risk factors for genital tract infections, including 
numbers of sexual partners, black race, and the absence of predominant vaginal lactobacilli.22, 85, 
86 A novel feature of our study was the evaluation of correlates for appropriate antibiotic use in 
non-pregnant women. 
 Major strengths of our study include the prospective longitudinal design and the large 
sample of 650 women with over 5500 visits. However, there were a few limitations. Antibiotic 
exposure in the last 2 months was ascertained by interview which is subject to recall error. 
However, a recent study reported 89% agreement between self-reported antibiotic use in the 
previous 3 months and pharmacy database records.87 The indications for antibiotic use were also 
identified through participant reports; therefore the diagnoses listed could not be confirmed. 
Information on whether diagnostic tests were performed was also lacking. Thus, it was likely that 
some cases of urinary tract infections and pharyngitis may not have been due to bacterial 
infections as was assumed for the analyses in this study. Therefore, the amount of inappropriate 
antibiotic use may have been underestimated. While this study identified participant factors that 
were independently associated with antibiotic use, no information on the types of providers who 
provided the prescriptions was available. Many studies have found that health provider 
characteristics, such as age, specialty, and practice type influence antibiotic prescribing.10, 84, 88 
Finally, this was a young, sexually active population which limits generalizability of results; 
results may not be applicable to pregnant or older women.  
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 Antibiotic use is widespread among reproductive-aged, non-pregnant women. While the 
majority of the antibiotic use was appropriate given that the primary indications were 
genitourinary infections, broad-spectrum agents were often selected to treat URI conditions for 
which antibiotics provide little therapeutic benefit. Since little is known about the impact of 
antimicrobial use on selection for antibiotic resistant strains and adversely affecting the healthy 
microbiome, educational efforts to promote judicious use of antibiotics tailored to non-pregnant 
women and their healthcare providers would have broad public health benefit. Furthermore, 
preventing acquisition of sexually transmitted infections would have the cross benefit of 
reducing overall antibiotic exposure in women. 
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4.7 TABLES 
 
Table 4.1 Antibiotic use by class 
Antibiotic Class 
No. of Prescriptions 
Reported  
Antibiotic Use Rate* 
(95% CI) 
Total prescriptions 699 81.2 (75.4-87.5) 
   
Metronidazole 169 (24.2%) 19.6 (16.9-22.8) 
   
Penicillins 158 (22.6%) 18.4 (15.7-21.5) 
   
Macrolides 106 (15.2%) 12.3 (10.2-14.9) 
   
Fluoroquinolones 61 (8.7%) 7.1 (5.5-9.1) 
   
Cephalosporins 57 (8.2%) 6.6 (5.1-8.6) 
   
Sulfonamides 47 (6.7%) 5.5 (4.1-7.3) 
   
Tetracyclines 42 (6.0%) 4.9 (3.6-6.6) 
   
Nitrofurantoin 18 (2.6%) 2.1 (1.3-3.3) 
   
Lincosamides 10 (1.4%) 1.2 (0.6-2.2) 
   
Aminoglycosides 1 (0.1%) 0.1 (0.02-0.8) 
   
Unknown 30 (4.3%) 3.5 (2.4-5.0) 
* Number of antibiotic prescriptions per 100 person-years 
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Table 4.2 Antibiotic use by class and indication 
Category 
No. of 
Prescriptions 
(N=699) 
MTZ 
N=169 
PCN 
N=158 
MAC 
N=106 
QUIN 
N=61 
CEPH 
N=57 
Other* 
N=148 
Genitourinary infection 339 (48.5%) 163 (96.4%) 7 (4.4%) 30 (28.3%) 38 (62.3%) 22 (38.6%) 79 (53.4%) 
  Bacterial vaginosis 144 (20.6%)† 143 (84.6%)† 0 0 0 0 1 (0.7%) 
  Urinary tract infection  93 (13.3%) 0 3 (1.9%) 2 (1.9%) 26 (42.6%) 1 (1.7%) 61 (41.2%) 
  Sexually transmitted infection 76 (10.9%)† 20 (11.8%)† 0 27 (25.5%) 8 (13.1%) 16 (28.1%) 5 (3.4%) 
  Pelvic inflammatory disease 11 (1.6%) 4 (2.4%) 2 (1.3%) 1 (0.9%) 1 (1.6%) 1 (1.7%) 2 (1.4%) 
  Other 19 (2.7%) 0 2 (1.3%) 0 3 (4.9%) 4 (7.0%) 10 (6.8%) 
        
Upper respiratory infection 183 (26.2%) 0 81 (51.3%) 63 (59.4%) 14 (23.0%) 8 (14.0%) 17 (11.5%) 
  Pharyngitis 30 (4.3%) 0 20 (12.7%) 6 (5.7%) 0 2 (3.5%) 2 (1.4%) 
  Pneumonia 5 (0.7%) 0 0 3 (2.8%) 1 (1.6%) 1 (1.7%) 0 
  Bronchitis 28 (4.0%) 0 6 (3.8%) 15 (14.2%) 4 (6.6%) 0 3 (2.0%) 
  Rhinosinusitis 69 (9.9%) 0 37 (23.4%) 19 (17.9%) 6 (9.8%) 1 (1.7%) 6 (4.1%) 
  Non-specific‡ 51 (7.3%) 0 18 (11.4%) 20 (18.9%) 3 (4.9%) 4 (7.0%) 6 (4.1%) 
        
Dental indications 67 (9.6%) 0 52 (32.9%) 5 (4.7%) 0 1 (1.7%) 9 (6.1%) 
  Dental cleaning prophylaxis 6 (0.9%) 0 6 (3.8%) 0 0 0 0 
  Dental infection 19 (2.7%) 0 14 (8.9%) 2 (1.9%) 0 1 (1.7%) 2 (1.4%) 
  Tooth extraction/surgery 22 (3.1%) 0 17 (10.8%) 2 (1.9%) 0 0 3 (2.0%) 
  Tooth or gum abscess 14 (2.0%) 0 10 (6.3%) 1 (0.9%) 0 0 3 (2.0%) 
  Tooth pain 6 (0.9%) 0 5 (3.2%) 0 0 0 1 (0.7%) 
        
Skin conditions 56 (8.0%) 0 5 (3.2%) 2 (1.9%) 1 (1.6%) 17 (29.8%) 31 (20.9%) 
  Abscess/cellulitis 12 (1.7%) 0 2 (1.3%) 0 0 9 (15.8%) 1 (0.7%) 
  Acne 19 (2.7%) 0 0 1 (0.9%) 0 1 (1.7%) 17 (11.5%) 
  Dermatitis/rash 8 (1.1%) 0 2 (1.3%) 0 0 3 (5.3%) 3 (2.0%) 
  Infection 9 (1.3%) 0 0 0 1 (1.6%) 2 (3.5%) 6 (4.1%) 
  Wound 8 (1.1%) 0 1 (0.6%) 1 (0.9%) 0 2 (3.5%) 4 (2.7%) 
        
Other indications§ 54 (7.7%) 6 (3.6%) 14 (8.9%) 6 (5.7%) 9 (14.8%) 8 (14.0%) 12 (8.1%) 
  Gastrointestinal indications 22 (3.1%) 6 (3.6%) 0 2 (1.9%) 7 (11.5%) 2 (3.5%) 5 (3.4%) 
  Ear infection 15 (2.1%) 0 11 (7.0%) 3 (2.8%) 1 (1.6%) 0 0 
  Eye infection 3 (0.4%) 0 0 1 (0.9%) 1 (1.6%) 0 1 (0.7%) 
  Musculoskeletal indications 4 (0.6%) 0 1 (0.6%) 0 0 3 (5.3%) 0 
  Miscellaneous indications 10 (1.4%) 0 1 (0.6%) 0 0 3 (5.3%) 6 (4.1%) 
MTZ, metronidazole; PCN, penicillins; MAC, macrolides; QUIN, fluoroquinolones; CEPH, cephalosporins 
*Other antibiotics included tetracyclines, sulfonamides, nitrofurantoin, lincosamides, aminoglycosides, and unknown. 
† 4 women had concomitant diagnoses of bacterial vaginosis and Trichomonas vaginalis and treated with metronidazole. 
‡ Non-specific upper respiratory infection included cold, cough, flu, laryngitis, nasal infection, sore throat, tonsillitis, upper respiratory infection. 
§ Gastrointestinal indications included appendicitis (n=3), diarrhea (n=2), gastroenteritis (n=2), H. pylori infection (n=2), surgery prophylaxis (n=3), stomach virus (n=1), typhoid 
fever (n=3), inflamed small intestine (n=2), abdominal abscess (n=2), and food infection prophylaxis (n=2); musculoskeletal indications included fracture (n=2), sprained wrist 
(n=1), and motor vehicle accident (n=1); miscellaneous indications included unspecified infection prophylaxis (n=2), Lyme disease (n=1), malaria prophylaxis (n=1), mastitis 
(n=2), surgery prophylaxis (n=2), and swollen lymph glands (n=2).
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Table 4.3 Independent risk factors for receiving antibiotics for bronchitis, rhinosinusitus, 
or non-specific upper respiratory tract infection (N=229 women) 
 
 
Variable 
No. URI 
events* 
(N=340) 
No (%) Treated 
with Antibiotic 
(n=143) 
Unadjusted 
RR (95% CI) 
Adjusted* 
RR (95% CI) 
Site     
  Pittsburgh, PA 251 104 (41.4) Referent  
  Augusta, GA 64 34 (53.1) 1.27 (0.94-1.72)  
  Houston, TX 25 5 (20.0) 0.41 (0.11-0.81)  
     
Race     
  White 235 110 (46.8) 1.47 (1.03-2.08) 1.51 (1.08-2.10) 
  Non-white 105 33 (31.4) Referent Referent 
     
Age, years     
  18-19 24 7 (29.2) Referent Referent 
  20-24 142 51 (35.9) 1.33 (0.59-2.96) 1.35 (0.62-2.94) 
  25-29 104 46 (44.2) 1.66 (0.74-3.70) 1.66 (0.76-3.63) 
  30-34 44 23 (52.3) 1.84 (0.79-4.28) 1.88 (0.83-4.24) 
  35-40 26 16 (61.5) 2.29 (0.99-5.29) 2.42 (1.05-5.57) 
     
Education, years     
  8-12 86 38 (44.2) Referent  
  13-16 198 84 (42.4) 1.01 (0.73-1.41)  
  17 or more 56 21 (37.5) 0.84 (0.52-1.36)  
URI, bronchitis, rhinosinusitus, or non-specific upper respiratory tract infection; RR, relative 
risk; CI, confidence interval 
*Adjusted for race and age.  
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Table 4.4 Antibiotic use rates by demographic and behavioral characteristics (N=699 prescriptions) 
 
Variable 
No. of 
Prescriptions 
Woman-years 
Antibiotic Use 
Rate* 
Unadjusted IRR 
(95% CI) 
Site     
  Pittsburgh, PA 551 593.7 92.8 Referent 
  Augusta, GA 116 234.3 49.5 0.53 (0.42-0.68) 
  Houston, TX 32 32.8 97.6 1.01 (0.69-1.47) 
Vaccine arm     
  Tetanus-diphtheria 362 438.1 82.6 Referent 
  GBS type III 337 422.8 79.7 0.96 (0.79-1.18) 
Race     
  White 386 523.2 68.0 Referent 
  Black 264 279.9 94.3 1.27 (1.03-1.58) 
  Other 49 57.8 84.8 1.15 (0.77-1.74) 
Age, years     
  18-19 51 87.4 58.4 Referent 
  20-24 299 359.1 83.1 1.35 (0.91-2.00) 
  25-29 207 221.8 93.3 1.55 (1.04-2.31) 
  30-34 78 93.8 83.2 1.36 (0.84-2.19) 
  35-40 61 98.3 62.1 1.00 (0.61-1.66) 
Education, years     
  8-12 216 215.3 100.3 1.64 (1.21-2.23) 
  13-16 364 450.1 80.9 1.33 (1.02-1.74) 
  17 or more 119 195.4 60.9 Referent 
Employed     
  No 233 250.0 93.2 Referent 
  Yes 466 610.8 76.3 0.83 (0.68-1.02) 
Marital status     
  Single 586 693.4 84.5 Referent 
  Married 113 167.4 67.5 0.83 (0.63-1.07) 
Contraception since last visit†     
  None, spermicide, tubal ligation, or 
copper intrauterine device 
124 174.1 71.2 Referent 
  Barrier methods 151 180.4 83.7 1.18 (0.87-1.60) 
  Hormonal methods, not DMPA 352 416.1 84.6 1.28 (0.98-1.68) 
  DMPA 72 90.3 79.7 1.12 (0.75-1.65) 
New sex partner since last visit     
  No 628 798.0 78.7 Referent 
  Yes 71 62.9 112.9 1.38 (1.02-1.88) 
Number of sex partners since last visit     
  None 69 103.8 66.5 Referent 
  One 589 723.3 81.4 1.27 (0.95-1.71) 
  Two or more 41 33.7 121.7 1.67 (1.05-2.67) 
Nugent score at prior visit‡     
  Normal (0-3) 350 510.1 68.6 Referent 
  Intermediate (4-6) 127 129.4 98.1 1.43 (1.14-1.79) 
  Bacterial vaginosis (7-10) 222 214.1 103.7 1.57 (1.28-1.93) 
IRR, incidence rate ratio; CI, confidence interval, DMPA, depot medroxyprogesterone acetate 
* Prescribing rate is per 100 person-years. 
† Barrier methods (condoms, diaphragms, cervical caps); hormonal methods, not DMPA (oral contraceptive tablets, 
vaginal rings, intrauterine devices containing levonorgestrel, transdermal patches, implants). 
‡ Nugent score missing for 9 visits  
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Table 4.5 Independent risk factors for antibiotic use, excluding use for upper respiratory 
tract infections (N=516 prescriptions) 
 
Variable 
Adjusted* IRR 
(95% CI) 
P-value 
Site  <0.001 
  Pittsburgh, PA Referent  
  Augusta, GA 0.49 (0.36-0.66)  
  Houston, TX 0.87 (0.56-1.36)  
   
Race  0.004 
  White Referent  
  Black 1.48 (1.15-1.90)  
  Other 1.18 (0.69-2.01)  
   
Age, years  0.001 
  18-19 Referent  
  20-24 1.29 (0.80-2.09)  
  25-29 1.29 (0.78-2.13)  
  30-34 0.94 (0.52-1.70)  
  35-40 0.73 (0.40-1.35)  
   
Number of sex partners since last visit  <0.001 
  None Referent  
  One 1.48 (1.03-2.14)  
  Two or more 2.04 (1.19-3.50)  
   
Abnormal Nugent score at prior visit (4-10) 1.80 (1.45-2.24) <0.001 
IRR, incidence rate ratio; CI, confidence interval; 
*Adjusted for study site, race, age, number of sex partners, and Nugent score 
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5.1 ABSTRACT 
 
Objective: To evaluate the association of class-specific antibiotic use with vaginal and rectal 
Lactobacillus colonization among non-pregnant women. 
Study Design: 650 a symptomatic women were followed bi-monthly for up to 18 m onths in a 
randomized vaccine trial. Antibiotic use and vaginal and rectal swabs for culture detection of 
lactobacilli were obtained at each visit. Generalized estimating equations and multinomial 
logistic regression were used to evaluate risk factors for vaginal and rectal colonization by 
lactobacilli. 
Results: The self-reported antibiotic use rate was 81.2 per 100 woman-years. Women were 
colonized by hydrogen peroxide (H2O2)-producing lactobacilli in the vagina and rectum at 3941 
(70.4%) and 3514 (62.8%) of 5597 follow-up visits, respectively. After adjusting for vaccine arm, 
race, age, education, and contraceptive method, women who used β-lactam antibiotics in the 
previous 14 days had a 45% decreased odds of vaginal colonization by H2O2-producing 
lactobacilli (95% confidence interval (CI): 0.38-0.78) than women who denied antibiotic 
exposure. β-lactam use was associated with a ~34% decreased odds of  rectal colonization, 
irrespective of time since exposure, after adjustment for vaccine arm, age, and race. For the three 
predominant H2O2-producing species, β-lactam use was associated with decreased vaginal L. 
jensenii and L. gasseri colonization, and decreased rectal colonization by L. crispatus and L. 
gasseri. Use of other classes of antibiotics did not significantly impact colonization by H2O2-
producing lactobacilli. 
Conclusion: In this population of women having a high antibiotic use burden, the use of β-lactam 
antibiotics was associated with reduced colonization by H2O2-producing lactobacilli in both the 
vagina and rectum. 
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5.2 INTRODUCTION 
 
Although antibiotics are one of the most commonly prescribed classes of medications, it is 
estimated that about half of antibiotic use is either unnecessary or sub-optimally effective as 
prescribed.3 Widespread antibiotic use in humans and in commercial agriculture has contributed 
to the emergence of antibiotic resistant bacteria. The Centers for Disease Control and Prevention 
recently classified antibiotic resistant bacteria according to their potential impact on public health 
and drug resistant Neisseria gonorrhoeae was assigned the highest threat level of urgent. In 
2011, 246,000 N. gonorrhoeae isolates, representing 30% of cases of gonococcal infections in 
the US, were resistant to at least one antibiotic commonly used for treatment. If not controlled, 
the spread of drug resistant N. gonorrhoeae infections could result in an estimated additional 
75,000 cases of pelvic inflammatory disease, a major cause of infertility, and 222 human 
immunodeficiency viral (HIV) infections over the next 10 years.3  
 In addition to contributing to an increase in multidrug resistant pathogens, antibiotic use 
also has a deleterious impact on commensal bacteria which colonize the gastrointestinal, 
respiratory and reproductive tracts. Lactobacillus species are the predominant bacteria in the 
healthy vaginal microbiome, and Lactobacillus crispatus have been shown to be an important 
predictor of a stable vaginal microbiome.15 Women who harbor hydrogen peroxide–producing 
lactobacilli in the vagina and/or the rectum have a reduced incidence of bacterial vaginosis, 
which is the most common vaginal syndrome among reproductive-age women.16, 17 Bacterial 
vaginosis is characterized by the absence of lactobacilli and the overgrowth of Gardnerella 
vaginalis and a diverse group of anaerobic bacteria, and is associated with increased acquisition 
of sexually transmitted infections including N. gonorrhoeae, HIV, herpes simplex virus type 2, 
Chlamydia trachomatis, and Trichomonas vaginalis.18-22 
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 It is unclear whether antibiotics being used in women have a deleterious impact on 
vaginal lactobacilli and thereby increase their risk for acquiring vaginal infections. There have 
been few studies which evaluated the effect of antimicrobial use on vaginal colonization by 
Lactobacillus beyond those used for the treatment of bacterial vaginosis.23, 24 Recent self-
reported antibiotic use was associated with reduced vaginal Lactobacillus colonization in two 
prospective cohort studies.14, 25 However, susceptibility patterns vary by antibiotic class and 
studies that have prospectively assessed the effect of specific antibiotics on vaginal Lactobacillus 
colonization have been limited by small sample sizes.26-32  Furthermore, the association between 
antibiotic use and rectal Lactobacillus colonization has not been evaluated. Since the rectum is 
considered a reservoir for many species of bacteria which colonize the vagina, it would be 
important to determine whether antibiotic use affects Lactobacillus colonization at this site. The 
objective of this longitudinal study was to evaluate the association of class-specific antibiotic use 
with vaginal and rectal Lactobacillus colonization among non-pregnant women. 
 
5.3 METHODS 
 
5.3.1 Study population 
 
This is a secondary analysis of a randomized, clinical trial designed to evaluate the efficacy of a 
group B Streptococcus (GBS) serotype III polysaccharide-tetanus toxoid conjugated vaccine. 
Briefly, non-pregnant, sexually active women aged 18-40 years who were using effective birth 
control methods, denied antimicrobial and antifungal use in the past 7 days, and were GBS 
culture-negative both vaginally and rectally were recruited from primary care and family 
planning settings in Pittsburgh, PA, Augusta, GA, and Houston, TX. Participants (n=663) were 
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randomized to receive a single dose of GBS type III- tetanus toxoid vaccine or a licensed vaccine 
containing tetanus and diphtheria toxoids adsorbed for adult use. The clinical trial was approved 
by the institutional review boards of the participating institutions. All participants provided 
written informed consent. The trial enrollment occurred from July 2003 to August 2006, and all 
follow-up visits were completed by February 2008. 
 
5.3.2 Antibiotic use and Lactobacillus identification 
 
Vaginal and rectal swabs for culture detection of lactobacilli and demographics, behavioral 
information, and use of systemic or intra-vaginal antimicrobials, were collected by pelvic 
examination and interview at enrollment, 1- and 2-months, and then bi-monthly for 18 months. 
Antimicrobial use was categorized by antibiotic class and by mechanism of action as follows: β-
lactams (penicillins and cephalosporins); protein synthesis inhibitors (macrolides, lincosamides, 
tetracyclines); nucleic acid synthesis inhibitors (fluoroquinolones, nitrofurantoin); and others 
(sulfonamides, class not determined). Lactobacillus were isolated and identified by colony and 
Gram stain morphology. Hydrogen peroxide (H2O2) detection of the Lactobacillus spp isolated 
was performed by a qualitative method in which isolates are inoculated onto a brucella agar base 
supplemented with 3,3’,5,5’-tetramethylbenzidine and horseradish peroxidase. Anaerobic 
incubation at 37°C for 48 to 72 hours followed by exposure to air for 30 minutes results in a blue 
pigment if there is H2O2 production and no pigment if H2O2 production is absent.
89  The 
lactobacilli isolated from women in the tetanus-diphtheria vaccine arm were identified to the 
species level using repetitive sequence polymerase chain reaction fingerprinting or 16S-rDNA 
PCR for restriction fragment length polymorphism (RFLP) analysis using HaeIII (Promega, 
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Madison, WI) and HpyCH4V (New England Biolab, Ipswich, MA) restriction enzymes. The 
RFLP patterns for each species were confirmed by sequencing the 16S rDNA.90  
 
5.3.3 Covariates 
 
Variables considered as potential explanatory factors included study site, vaccine arm, race, age, 
education, and marital and employment status at enrollment. Other variables which could change 
over time and for which data was collected at each visit included number of male sexual 
partners, new sex partner, frequency of vaginal intercourse, douching, antibiotic use, and 
contraceptive methods. Contraceptives were categorized as: none, non-barrier methods 
(spermicides, tubal ligations, or copper intrauterine devices), barrier methods (condoms, 
diaphragms, or cervical caps), hormonal methods (oral contraceptive tablets, intrauterine devices 
containing levonorgestrel, the vaginal ring, transdermal patches, or implants), and depot 
medroxyprogesterone acetate (DMPA). 
 
5.3.4 Statistical analysis 
 
Statistical analyses were performed using Stata statistical software release 11.2 (Stata Corp., 
College Station, TX), and statistical tests were evaluated at the 0.05 two-sided significance level. 
All women who completed at least one follow-up visit (N=650) were included in the analyses. A 
population averaged generalized estimating equations regression model based on the repeated 
visit measures per woman was used to evaluate risk factors for vaginal and rectal colonization by 
H2O2-producing Lactobacillus and estimate the population averaged odds ratios (OR). An 
exchangeable working correlation matrix was specified and modified sandwich estimates of the 
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variance were calculated.78 Variables were retained in the model if the P value from the Wald 
chi-squared test statistic was 0.05 or less. The final models were also adjusted for age. 
Generalized estimating equations regression was also used to evaluate the association between 
antibiotic use and vaginal colonization by L. iners. Multinomial logistic regression was used to 
evaluate the association between antibiotic use and vaginal and rectal colonization by L. 
crispatus, L. jensenii, and L. gasseri. Because women can be concurrently colonized by multiple 
species of lactobacilli, the Lactobacillus species-specific colonization outcome was defined as 
follows: absence of L. crispatus, L. jensenii, and L .gasseri (the reference category); presence of 
L. crispatus; presence of L. jensenii in the absence of L. crispatus; and presence of L. gasseri in 
the absence of both L. crispatus and L. jensenii. The 95% confidence intervals were based on the 
robust estimator of the standard errors which accounted for the repeated measures per woman. 
 
5.4 RESULTS 
 
This analysis included 650 w omen who completed 5599 follow-up visits over 860.8 w oman-
years. Most women (60%) completed all 10 scheduled follow-up visits and 91% completed 5 or 
more visits; the median follow-up time was 1.5 years. There were no differences in demographic 
characteristics between women who completed all study visits and those that did not with the 
exception of age. Women who completed all scheduled visits were slightly older than those with 
fewer than 10 visits (26.6+5.8 years and 24.4+5.2 years, respectively, p<0.001). Antimicrobial 
use was reported by 341 (52.5%) women at least once and at 605 (10.8%) of the follow-up visits. 
Women reported using a total of 699 antibiotic prescriptions for an overall antibiotic use rate of 
81.2 per 100 woman-years of follow-up (95% confidence interval (CI): 75.4-87.5). The use of 
more than one antibiotic was reported at 75 visits; 2 at 52 visits, 3 at 21 visits, and 4 at 2 visits. 
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The most commonly reported antibiotics used were β-lactams (30.8%), metronidazole (24.2%), 
and protein synthesis inhibitors (22.6%, Table 5.1). The majority of antibiotics were used to treat 
genitourinary conditions (48.5%); primarily bacterial vaginosis (20.6%), urinary tract infections 
(13.3%), and sexually transmitted infections (10.9%). However, upper respiratory tract infections 
accounted for 26.2% of all antibiotic use and 41.4% of the use of β-lactam agents. 
 Vaginal and rectal swab specimens for Lactobacillus culture were not evaluable for two 
visits, so the following analyses included 5597 visits. Women were colonized by H2O2-
producing lactobacilli in the vagina at 3941 (70.4%) and in the rectum at 3514 (62.7%) of the 
follow-up visits. The univariate associations between demographics and contraceptive methods 
with vaginal and rectal colonization by H2O2-producing Lactobacillus are shown in Table 5.2.   
 Non-white race and having less than 17 years of education were associated with reduced 
colonization by H2O2-producing lactobacilli at either anatomical site. Women who used 
hormonal contraception methods, not including DMPA, were more likely to be vaginally or 
rectally colonized by H2O2-producing lactobacilli than women who used no contraception, 
spermicides, or copper intrauterine devices and those who had tubal ligations. DMPA use was 
not significantly associated with Lactobacillus colonization. Women who received the GBS type 
III vaccine were more likely to be colonized by H2O2-producing lactobacilli in the rectum than 
women who received the tetanus-diphtheria vaccine (Table 5.2). Age, marital and employment 
status, douching in the past 30 days, and sexual activity were not associated with Lactobacillus 
colonization (p>0.05). 
 While overall antibiotic use was not associated with Lactobacillus colonization, women 
who used β-lactams had a 26% decreased odds of colonization by H2O2-producing lactobacilli in 
the vagina (95% CI: 0.58-0.95) and a 34% decreased odds of colonization in the rectum (95% 
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CI: 0.51-0.85) than women who denied antibiotic exposure since their last visit in the unadjusted 
analyses (Table 5.3). Other classes of antibiotics were not significantly associated with H2O2-
producing Lactobacillus colonization. After taking into account time since last dose, more recent 
exposure to β-lactams (within 14 days) was associated with a 44% decrease in the odds of 
colonization by H2O2-producing lactobacilli in the vagina, while exposure >14 days was not 
associated (odds ratio (OR)=0.94). Time since exposure to β-lactams did not alter the magnitude 
of the association of β-lactam antibiotics with rectal Lactobacillus colonization (Table 5.3), even 
when time since last dose was categorized by 10 day intervals up to 30 days and then by >30 
days (data not shown).   
 Antibiotic use, race, education, and contraceptive methods were independently associated 
with vaginal colonization by H2O2-producing lactobacilli (Table 5.4). The use of β-lactam 
antibiotics in the previous 14 days remained associated with reduced colonization by H2O2-
producing lactobacilli in the vagina (adjusted odds ratio (aOR) =0.55, 95% CI: 0.38-0.78) 
compared to no antibiotic exposure. Other classes of antibiotics and β-lactam use >14 days were 
not significantly associated with decreased vaginal Lactobacillus colonization. Women with 8-12 
years and 13-16 years of education were less likely to be colonized by H2O2-producing 
lactobacilli in the vagina compared to women with 17 years or more (aOR=0.46, 95% CI: 0.30-
0.69 and aOR=0.66, 95% CI: 0.46-0.96, respectively), while hormonal methods of 
contraception, excluding DMPA, was associated with an increased likelihood of colonization 
(aOR=1.31, 95% CI: 1.03-1.67) compared to non-barrier methods or no contraception. Black 
women were less likely than white women to be colonized at either site (vaginal adjusted odds 
ratio (aOR)=0.51, 95% CI: 0.39-0.66 and rectal aOR=0.63, 95% CI: 0.51-0.78). 
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 In addition to race, antibiotic use and vaccine arm were the factors independently 
associated with rectal colonization by H2O2-producing lactobacilli (Table 5.4). β-lactam 
antibiotic use, irrespective of time since last dose, was associated with a ~34% decrease in the 
odds of rectal colonization compared to women with no antibiotic exposure (<14 days 
aOR=0.65, 95% CI: 0.47-0.90 and >14 days aOR=0.66, 95% CI: 0.45-0.97). Women who 
received the GBS type III vaccine were more likely to be colonized by H2O2-producing 
lactobacilli in the rectum than women who received the tetanus-diphtheria vaccine (aOR=1.22, 
95% CI: 1.01-1.49). 
 To assess whether the antibiotic effects were specific to particular species of lactobacilli, 
the isolates were identified to the species level for the 330 women in the tetanus-diphtheria 
vaccine arm for a total of 2855 vi sits. The species-specific prevalence of vaginal and rectal 
colonization was: L. crispatus (39.4% and 33.6%); L. jensenii (28.0% and 13.2%); L. gasseri 
(22.3% and 26.2%); and L. iners (24.6% and 1.2%). While β-lactam use was not associated with 
a statistically significant decrease in vaginal colonization by L. crispatus, rectal colonization by 
L. crispatus was associated with β-lactam use >14 days (OR=0.51, 95% CI: 0.27-0.99, Table 
5.5). There was a 72% decrease in the odds of vaginal colonization by L. jensenii in the absence 
of L. crispatus colonization among women who used β-lactams in the last 14 days (95% CI: 
0.08-0.93) compared to women with no antibiotic exposure. While there was a similar decrease 
in rectal colonization by L. jensenii among women reporting recent β-lactam use, this association 
was not statistically significant. In women whose predominant Lactobacillus species was L. 
gasseri, recent β-lactam use was associated with ~80% decrease in the odds of colonization by L. 
gasseri in both the vagina and the rectum. Although β-lactam use did not alter colonization by L 
iners, use of protein synthesis inhibitors was associated with a 52% decreased odds of vaginal 
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colonization by this microorganism (95% CI: 0.25-0.90) compared to no antibiotic use (data not 
shown). 
 
5.5 DISCUSSION 
 
In this large prospective study of reproductive-aged women, the use of β-lactam antibiotics was 
associated with a 34 to 45% reduction in the odds of colonization by H2O2-producing lactobacilli 
in both the vagina and rectum, while other classes of antibiotics or overall self-reported antibiotic 
use were not associated with Lactobacillus colonization. Self-reported antibiotic use has been 
reported as a risk factor for loss of H2O2-producing lactobacilli in the vagina in two previous 
studies, and the magnitude of the association was similar in a Kenyan study of over 1000 sex 
workers.14, 25 However, both of these studies evaluated measures of overall antibiotic use and did 
not assess class-specific associations. Among three studies that did prospectively evaluate the 
use of penicillins in women without bacterial vaginosis, one found decreased colonization by 
vaginal lactobacilli one-week after discontinuation of therapy, while the other two studies found 
no change in vaginal Lactobacillus colonization.27-29 However, these three studies evaluated a 
combined total of 41 women. 
 The association between β-lactam use and rectal colonization by H2O2-producing 
lactobacilli did not vary by time since exposure, whereas only more recent use was associated 
with vaginal colonization in this study. These results suggest that the disruption of Lactobacillus 
colonization associated with the use of β-lactam antibiotics persists in the rectum for a longer 
period of time than in the vagina. Previous studies of perturbation of the distal gut microbiome 
following use of a fluoroquinolone have demonstrated that there is an incomplete rebound in the 
microbiota that persists for 2 to 6 months after discontinuation of antibiotic therapy.91 
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 The primary Lactobacillus species that produce hydrogen peroxide in the vagina are L. 
crispatus, L.jensenii, and L. gasseri.72 A recent study that assessed the susceptibility of vaginal 
and rectal Lactobacillus isolates to ampicillin, found that 80% of L. crispatus isolates, 87% of L. 
jensenii, and all L. gasseri isolates were susceptible to this β-lactam antibiotic in vitro.68 In the 
present study, while the use of β-lactam antibiotics was associated with reduced colonization by 
any H2O2-producing lactobacilli, species-specific analyses showed that the use of β-lactams was 
associated with decreased colonization by L. crispatus in the rectum but not in the vagina. 
Therefore, although 80% of L. crispatus isolates are susceptible to β-lactams in vitro, the use of 
β-lactams did not appear to have a sustained inhibitory effect on L. crispatus in vivo. This is an 
important finding since women who are colonized by L. crispatus have a reduced incidence of 
bacterial vaginosis, and thereby have a decreased risk of acquiring other vaginal infections.73, 74 
However, β-lactam use in the previous two weeks was associated with marked decreases in 
vaginal and rectal Lactobacillus colonization in women whose predominant H2O2-producing 
Lactobacillus species were L. jensenii or L. gasseri, which is consistent with their susceptibility 
to β-lactams. Most L. iners isolates do not  produce hydrogen peroxide.72 Unlike the 
predominantly H2O2-producing Lactobacillus species evaluated in this study, β-lactam use was 
not associated with decreased vaginal colonization by L. iners even though this species is 
susceptible to β-lactam antibiotics. However, the relative prevalence of L. iners was low, thus 
limiting the statistical power to detect changes in colonization following antibiotic therapy. L. 
iners colonization was decreased among women who used macrolides, lincosamides, or 
tetracyclines.   
 To date, this is the first study to assess the association of antibiotic use with rectal 
colonization by H2O2-producing lactobacilli. Women colonized by H2O2-producing lactobacilli 
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in both the vagina and rectum have a l ower prevalence of bacterial vaginosis than women 
colonized at only one of these sites, suggesting that the rectum is a reservoir for lactobacilli 
which colonize the vagina.17 Therefore, the finding that the use of β-lactam antibiotics is 
associated with reduced rectal as well as vaginal colonization by lactobacilli may have important 
public health implications in that women using these antimicrobial agents may be at increased 
risk for acquiring bacterial vaginosis. Since β-lactam antibiotics were often selected to treat 
upper respiratory tract infections for which antibiotics typically provide little therapeutic benefit, 
women and their healthcare providers should be aware that the inappropriate use of antibiotics 
may disrupt the normal microbiota and increase susceptibility to other infections. 
 Black women were less likely to be colonized by H2O2-producing lactobacilli in the 
vagina and the rectum, and women with an education attainment equivalent to less than a college 
graduate were less likely to be vaginally colonized in this study. This was not surprising since 
race and low educational attainment have been identified as correlates of vaginal Lactobacillus 
colonization and/or bacterial vaginosis in other studies.72, 92 Contraceptive methods that 
contained hormones, which included oral contraceptives, hormonal intrauterine devices, vaginal 
rings, transdermal patches, and implants was associated with an increased likelihood of vaginal 
colonization by H2O2-producing lactobacilli in this study. DMPA differs from other  hormonal 
contraceptives in that it has an anti-estrogenic effect on the vaginal epithelium, and this 
contraceptive method was not correlated with colonization by lactobacilli in the present study. 
Since there is an inverse relationship between Lactobacillus colonization and bacterial vaginosis, 
these findings are consistent with a recent meta-analysis of 55 studies, which found that 
hormonal contraceptive use, regardless of form, was associated with a reduced risk of bacterial 
vaginosis.93  
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 Major strengths of our study include the prospective longitudinal design, the large sample 
of 650 women with 5600 visits, and assessment of both vaginal and rectal Lactobacillus 
colonization by culture methods, and identification of the lactobacilli to the species level using 
16S sequencing based techniques. A limitation of this study was that antibiotic exposure in the 
last 2 months was ascertained during a structured interview, a method which is subject to recall 
error. However, a recent study reported 89% agreement between self-reported antibiotic use in 
the previous 3 months and pharmacy database records.87 Finally, this was a young, sexually 
active population which limits generalizability of results. 
 In this population of reproductive-aged women having a high antibiotic use burden, the 
use of β-lactam antibiotics was associated with reduced colonization by hydrogen peroxide-
producing lactobacilli in both the vagina and rectum. Since the use of some classes of antibiotics 
adversely affect the healthy vaginal microbiome, educational efforts to promote appropriate use 
of antibiotics tailored to non-pregnant women and their healthcare providers would have broad 
public health benefit. 
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5.7 TABLES 
 
Table 5.1 Antibiotic use by class 
 
Antibiotic Class 
No. of Prescriptions 
Reported  
Total prescriptions 699 
  
β-lactams 215 (30.8%) 
  Penicillins 158 (22.6%) 
  Cephalosporins 57 (8.2%) 
  
Metronidazole 169 (24.2%) 
  
Protein synthesis inhibitors 158 (22.6%) 
  Macrolides 106 (15.2%) 
  Tetracyclines 42 (6.0%) 
  Lincosamides 10 (1.4%) 
  
Nucleic acid synthesis inhibitors 79 (11.3%) 
  Fluoroquinolones 61 (8.7%) 
  Nitrofurantoin 18 (2.6%) 
  
Others 78 (11.2%) 
  Sulfonamides 47 (6.7%) 
  Aminoglycosides 1 (0.1%) 
  Unknown 30 (4.3%) 
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Table 5.2 Association of demographics and contraceptive methods with vaginal and rectal colonization by hydrogen peroxide-producing 
Lactobacillus 
 
Variable 
No. Total 
Visits 
(N=5597) 
Vaginal Colonization by H2O2-
producing Lactobacillus 
Rectal Colonization by H2O2-producing 
Lactobacillus 
No. (%) Visits 
Present 
(n=3941) 
Unadjusted OR 
(95% CI) 
No. (%) Visits 
Present 
(n=3514) 
Unadjusted OR 
(95% CI) 
Site      
  Pittsburgh, PA 3929 2750 (70.0) Referent 2449 (62.3) Referent 
  Augusta, GA 1441 1073 (74.5) 1.19 (0.89-1.61) 932 (64.6) 1.09 (0.87-1.38) 
  Houston, TX 227 118 (52.0) 0.43 (0.25-0.76) 133 (58.6) 0.79 (0.52-1.21) 
Vaccine arm      
  Tetanus-diphtheria  2855 1943 (68.1) Referent 1717 (60.1) Referent 
  GBS type III 2742 1998 (72.9) 1.25 (0.98-1.59) 1797 (65.5) 1.25 (1.03-1.52) 
Race      
  White 3385 2617 (77.3) Referent 2268 (67.0) Referent 
  Black 1830 1079 (59.0) 0.42 (0.32-0.54) 1024 (56.0) 0.63 (0.51-0.77) 
  Other 382 245 (64.1) 0.58 (0.36-0.92) 222 (58.1) 0.73 (0.51-1.05) 
Age, years      
  18-19 549 394 (71.8) Referent 358 (65.2) Referent 
  20-24 2318 1707 (73.6) 1.03 (0.64-1.65) 1528 (65.9) 1.00 (0.69-1.44) 
  25-29 1458 989 (67.8) 0.79 (0.48-1.29) 877 (60.2) 0.77 (0.52-1.13) 
  30-34 625 410 (65.6) 0.70 (0.40-1.24) 340 (54.4) 0.60 (0.38-0.94) 
  35-40 647 441 (68.2) 0.82 (0.47-1.43) 411 (63.5) 0.90 (0.58-1.39) 
Education, years      
  17 or more 1268 1019 (80.4) Referent 871 (68.7) Referent 
  13-16 2924 2104 (72.0) 0.62 (0.43-0.89) 1841 (63.0) 0.77 (0.59-1.01) 
  8-12 1405 818 (58.2) 0.35 (0.24-0.51) 801 (57.0) 0.60 (0.45-0.80) 
Contraception since last visit*      
  None or non-barrier methods 1093 672 (61.5) Referent 614 (56.2) Referent 
  Barrier methods 1188 768 (64.6) 0.99 (0.81-1.22) 716 (60.3) 0.99 (0.81-1.22) 
  Hormonal methods, not DMPA 2704 2104 (77.8) 1.45 (1.15-1.82) 1807 (66.8) 1.24 (1.01-1.53) 
  DMPA 612 397 (64.9) 1.10 (0.73-1.64) 377 (61.6) 1.21 (0.90-1.62) 
OR, odds ratio; CI, confidence interval; DMPA, depot medroxyprogesterone acetate 
*Non-barrier methods (spermicide, tubal ligation, copper intrauterine device); barrier methods (condoms, diaphragms, cervical caps); hormonal methods, not 
DMPA (oral contraceptive tablets, vaginal rings, intrauterine devices containing levonorgestrel, transdermal patches, implants). 
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Table 5.3 Association of antibiotic use with vaginal and rectal colonization by hydrogen peroxide-producing Lactobacillus 
 
Antibiotic use since last visit* 
No. Total 
Visits 
(N=5597) 
Vaginal Colonization by H2O2-
producing Lactobacillus 
Rectal Colonization by H2O2-
producing Lactobacillus 
No. (%) 
Visits 
Present 
(n=3941) 
Unadjusted OR 
(95% CI) 
No. (%) 
Visits 
Present 
(n=3514) 
Unadjusted OR 
(95% CI) 
None 4992 3518 (70.5) Referent 3140 (62.9) Referent 
      
Any antibiotic 605 423 (69.9) 1.01 (0.85-1.19) 374 (61.8) 0.92 (0.78-1.08) 
    >14 days since last dose 386 272 (70.5) 1.02 (0.84-1.24) 237 (61.4) 0.90 (0.74-1.09) 
    <14 days since last dose 219 151 (68.9) 0.98 (0.75-1.27) 137 (62.6) 0.95 (0.74-1.23) 
      
Class-specific antibiotic use      
  β-lactams 214 133 (62.1) 0.74 (0.58-0.95) 112 (52.3) 0.66 (0.51-0.85) 
      β-lactams, >14 days since last dose 121 84 (69.4) 0.94 (0.65-1.35) 64 (52.9) 0.65 (0.47-0.90) 
      β-lactams, <14 days since last dose 93 49 (52.7) 0.56 (0.40-0.78) 48 (51.6) 0.66 (0.45-0.97) 
  Protein synthesis inhibitors 130 104 (80.0) 1.33 (0.99-1.77) 96 (73.8) 1.19 (0.87-1.63) 
  Metronidazole 130 83 (63.8) 1.15 (0.77-1.71) 71 (54.6) 0.93 (0.64-1.34) 
  Nucleic acid synthesis inhibitors 68 53 (77.9) 1.02 (0.68-1.54) 52 (76.5) 1.54 (0.99-2.42) 
  Others 63 50 (79.4) 1.38 (0.88-2.15) 43 (68.3) 1.09 (0.65-1.84) 
OR, odds ratio; CI, confidence interval 
* β-lactams (penicillins, cephalosporins); protein synthesis inhibitors (macrolides, lincosamides, tetracyclines); nucleic acid synthesis 
inhibitors (fluoroquinolones, nitrofurantoin); others (sulfonamides, unknown)  
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Table 5.4 Independent risk factors for vaginal and rectal colonization by hydrogen peroxide-
producing Lactobacillus 
 
Factor 
Vaginal Colonization by 
H2O2-producing 
Lactobacillus 
Adjusted* OR (95% CI) 
Rectal Colonization by 
H2O2-producing 
Lactobacillus 
Adjusted* OR (95% CI) 
GBS serotype III vaccine arm 1.20 (0.94-1.54) 1.22 (1.01-1.49) 
   
Race   
  White Referent Referent 
  Black 0.51 (0.39-0.66) 0.63 (0.51-0.78) 
  Other 0.74 (0.45-1.21) 0.77 (0.53-1.10) 
   
Age, years   
  18-19 Referent Referent 
  20-24 0.91 (0.57-1.47) 1.03 (0.70-1.50) 
  25-29 0.68 (0.41-1.12) 0.80 (0.54-1.18) 
  30-34 0.70 (0.39-1.26) 0.63 (0.40-1.00) 
  35-40 1.01 (0.57-1.79) 1.01 (0.64-1.60) 
   
Education, years   
  17 or more Referent  
  13-16 0.66 (0.46-0.96)  
  8-12 0.46 (0.30-0.69)  
   
Contraception since last visit†   
  None or non-barrier methods  Referent  
  Barrier methods 1.03 (0.84-1.27)  
  Hormonal methods, not DMPA 1.31 (1.03-1.67)  
  DMPA 1.26 (0.85-1.86)  
   
Antibiotic use since last visit‡   
  None Referent Referent 
  Antibiotics other than β-lactams 1.23 (1.01-1.50) 1.13 (0.91-1.40) 
  β-lactams, >14 days since last dose 0.94 (0.64-1.39) 0.65 (0.47-0.90) 
  β-lactams, <14 days since last dose 0.55 (0.38-0.78) 0.66 (0.45-0.97) 
OR, odds ratio; CI, confidence interval; DMPA, depot medroxyprogesterone acetate 
* Vaginal colonization adjusted for vaccine arm, race, age, education and antibiotic use; rectal 
colonization adjusted for vaccine arm, race, age, and antibiotic use. 
† Non-barrier methods (spermicide, tubal ligation, copper intrauterine device); barrier methods (condoms, 
diaphragms, cervical caps); hormonal methods, not DMPA (oral contraceptive tablets, vaginal rings, 
intrauterine devices containing levonorgestrel, transdermal patches, implants). 
‡ β-lactams (penicillins, cephalosporins); all other antibiotics (macrolides, lincosamides, tetracyclines, 
fluoroquinolones, nitrofurantoin, sulfonamides, unknown).  
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Table 5.5 Vaginal and rectal colonization by Lactobacillus spp. and antibiotic use among women in the tetanus-diphtheria 
vaccine arm – multinomial logistic regression model (N=330 women) 
 
  Antibiotic use since last visit* 
No. Total 
Visits 
Vaginal Colonization by 
Lactobacillus spp 
Rectal Colonization by 
Lactobacillus spp. 
No. (%) 
Visits 
Present 
Unadjusted OR 
(95% CI) 
No. (%) 
Visits 
Present 
Unadjusted OR 
(95% CI) 
L. crispatus present 2855 1125 (39.4)  960 (33.6)  
  None 2544 1004 (39.5) Referent 865 (34.0) Referent 
  Antibiotics other than β-lactams 199 80 (40.2) 1.18 (0.82-1.71) 65 (32.7) 1.05 (0.73-1.52) 
  β-lactams, >14 days since last dose 59 19 (32.2) 0.76 (0.43-1.36) 13 (22.0) 0.51 (0.27-0.99) 
  β-lactams, <14 days since last dose 53 22 (41.5) 0.71 (0.40-1.28) 17 (32.1) 0.65 (0.36-1.18) 
      
L. jensenii present, L. crispatus absent 2855 390 (13.7)  219 (7.7)  
  None 2544 350 (13.8) Referent 194 (7.6) Referent 
  Antibiotics other than β-lactams 199 31 (15.6) 1.31 (0.80-2.16) 18 (9.0) 1.30 (0.69-2.47) 
  β-lactams, >14 days since last dose 59 6 (10.2) 0.69 (0.27-1.76) 5 (8.5) 0.88 (0.33-2.35) 
  β-lactams, <14 days since last dose 53 3 (5.7) 0.28 (0.08-0.93) 2 (3.8) 0.34 (0.08-1.42) 
      
L. gasseri present, L. crispatus and L. 
jensenii absent 2855 390 (13.7)  519 (18.2)  
  None 2544 344 (13.5) Referent 462 (18.2) Referent 
  Antibiotics other than β-lactams 199 31 (15.6) 1.34 (0.86-2.09) 43 (21.6) 1.30 (0.85-2.00) 
  β-lactams, >14 days since last dose 59 13 (22.0) 1.52 (0.70-3.30) 11 (18.6) 0.81 (0.42-1.57) 
  β-lactams, <14 days since last dose 53 2 (3.8) 0.19 (0.04-0.82) 3 (5.7) 0.21 (0.05-0.98) 
OR, odds ratio; CI, confidence interval 
* β-lactams (penicillins, cephalosporins); all other antibiotics (macrolides, lincosamides, tetracyclines, fluoroquinolones, 
nitrofurantoin, sulfonamides, unknown). 
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6.1 ABSTRACT 
 
Objective: To evaluate risk factors for vulvovaginal candidiasis (VVC) in non-pregnant women. 
Study Design: 650 a symptomatic women were followed bi-monthly for up to 18 months in a 
prospective cohort study. Behavioral information and antimicrobial and antifungal use were 
collected by interview. The risk of VVC, defined as clinician diagnosed yeast vaginitis or self-
diagnosis with documented antifungal use, was evaluated using Andersen-Gill proportional 
hazards models for repeated events. 
Results: The antibiotic use rate was 81/100 woman-years. There were 205 episodes of VVC over 
860.8 woman-years for an incidence of 24/100 woman-years. After adjusting for age, number of 
sexual partners, and contraceptive method, women who used β-lactams (adjusted hazard ratio 
(aHR) =3.16, 95% confidence interval (CI): 2.06–4.86), metronidazole (aHR=2.52, 95% CI: 
1.40–4.53), or fluoroquinolones and nitrofurantoin (aHR=2.31, 95% CI: 1.03–5.18) were more 
likely to develop VVC compared to women who did not use antibiotics. Other classes of 
antibiotics were not associated with VVC. Women using depot medroxyprogesterone acetate 
were 67% less likely to acquire VVC (aHR=0.33, 95% CI: 0.12–0.90) compared to women not 
using barrier or hormonal contraception. Other forms of hormonal contraception (tablets, vaginal 
rings, intrauterine devices, transdermal patches, and implants) were not associated with VVC. 
Compared to sexually abstinent women, women having multiple sex partners had an increased 
risk of VVC (aHR=4.59, 95% CI=1.87-11.28).  
Conclusion: In this population of women having a high antibiotic use burden, the incidence of 
VVC varied by antibiotic class. Antibiotics, multiple sexual partners, and contraceptive choice 
influence the incidence of VVC. 
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6.2 INTRODUCTION 
 
Vulvovaginal candidiasis (VVC) is characterized by vulval itching and abnormal vaginal 
discharge and is the second most common cause of vaginitis in reproductive aged women. It is 
estimated that as many as three out of four women will have VVC at least once in their 
lifetime.33 The prevalence of yeast colonization is 20-25% among women of childbearing age 
with vaginal symptoms, while 10% of women are asymptomatically colonized by yeast in the 
vagina.34, 35 Among women reporting an initial yeast infection, 10-25% reported 4 or  more 
recurrent infections per year.36 In addition to the discomfort and costs associated with VVC, 
some prospective studies have shown an increased risk of HIV acquisition among women who 
had VVC at the visit prior to seroconversion, independent of other risk factors. 38, 39 
 While the pathogenesis of VVC remains unclear, several risk factors have been identified 
including systemic antimicrobial use, oral contraceptives, and vaginal Lactobacillus 
colonization.33 However, the results of these studies have been inconsistent, particularly for 
antimicrobial use. A longitudinal study of 316 asymptomatic, non-pregnant women found no 
association between any antibiotic use and clinician-diagnosed or self-diagnosed yeast 
vaginitis.46 A second case-control study of 691 women also reported  no association between 
antibiotic use and culture-proven VVC.45 By contrast, a  prospective study of  80  women 
reported an association between any antibiotic use and increased incidence of VVC.41 While a  
case-control study of 1,585 women also found an increased risk of VVC among women 
reporting any antibiotic use within the prior month, this association did not vary by antibiotic 
class.43 The objective of this longitudinal study was to evaluate risk factors for VVC in non-
pregnant women, with particular emphasis on class-specific antibiotic use and contraceptive 
methods. 
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6.3 METHODS 
 
6.3.1 Study population 
 
This is a secondary analysis of a randomized, clinical trial designed to evaluate the efficacy of a 
group B Streptococcus (GBS) serotype III polysaccharide-tetanus toxoid conjugated vaccine. 
Non-pregnant, sexually active women aged 18-40 years who were using effective birth control 
methods and were GBS culture-negative both vaginally and rectally were recruited from primary 
care and family planning settings in Pittsburgh, PA, Augusta, GA, and Houston, TX. Participants 
(n=663) were randomized to receive a single dose of GBS type III- tetanus toxoid vaccine or a 
licensed vaccine containing tetanus and diphtheria toxoids adsorbed for adult use. The clinical 
trial was approved by the institutional review boards of the participating institutions. All 
participants provided written informed consent. Enrollment occurred from July 2003 to August 
2006, and all follow-up visits were completed by February 2008. 
 At the time of enrollment, women denied antimicrobial and antifungal use in the past 7 
days and did not have VVC. Vaginal swabs for culture detection of lactobacilli, demographics, 
use of systemic or intra-vaginal antimicrobials and antifungals, contraceptive methods, and 
sexual activity were collected by pelvic examination and interview at enrollment, 1- and 2-
months, and then bi-monthly for 18 months.  
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6.3.2 Vulvovaginal candidiasis and antibiotic use 
 
VVC was defined as the report of a clinician-diagnosed yeast infection or self-diagnosed yeast 
infection with use of an antifungal documented by research personnel.  Antimicrobial use was 
categorized by antibiotic class, and by mechanism of action as follows: β-lactams (penicillins, 
cephalosporins); protein synthesis inhibitors (macrolides, lincosamides, tetracyclines); nucleic 
acid synthesis inhibitors (fluoroquinolones, nitrofurantoin); and others (sulfonamides, class 
unknown). For all cases of VVC, participant records were reviewed to verify that the initiation of 
antimicrobial use preceded the onset of VVC. Lactobacillus were isolated and identified by 
methods that have been previously described.76 
 
6.3.3 Covariates 
 
The variables considered for analyses were study site, study arm, race, age, education, and 
marital and employment status at enrollment. Other variables which could change over time and 
for which data was collected at each visit included number of male sexual partners, new sex 
partner, frequency of vaginal intercourse, receptive anal intercourse, douching, Nugent score77, 
vaginal Lactobacillus colonization, antibiotic use, and contraceptive methods. Contraceptives 
were categorized as none, non-barrier methods (spermicides, tubal ligations, or copper 
intrauterine devices), barrier methods (condoms, diaphragms, or cervical caps), hormonal 
methods (oral contraceptive tablets, intrauterine devices containing levonorgestrel, the vaginal 
ring, transdermal patches, or implants) and depot medroxyprogesterone acetate (DMPA).  
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6.3.4 Statistical analysis 
 
Statistical analyses were performed using Stata statistical software release 11.2 (Stata Corp., 
College Station, TX), and statistical tests were evaluated at the 0.05 two-sided significance level. 
All women who completed at least one follow-up visit (N=650) were included in the analyses. 
Andersen-Gill proportional hazards models for repeated events were used to evaluate the factors 
associated with the incidence of VVC. Efron’s method was used for handling tied failure times 
and the variance estimates were calculated using the method of Lin and Wei.78, 94 Variables were 
considered for inclusion in multivariable models if the P value from the unadjusted model was 
less than 0.2. Variables were retained in the model if the P value from the Wald chi-squared test 
statistic was 0.05 or less. The final models were also adjusted for age. The proportional-hazards 
assumptions of the final models were tested on the basis of the scaled Schoenfeld residuals.95  
 
6.4 RESULTS 
 
This analysis included 650 w omen who completed 5599 f ollow-up visits over 860.8 w oman-
years. Most women (60%) completed all 10 scheduled follow-up visits and 91% completed 5 or 
more visits; the median follow-up time was 1.5 years. There were 205 episodes of VVC for an 
incidence of 24 per 100 woman-years (95% confidence interval (CI): 21-27). Of the 205 
episodes, 164 were clinician diagnosed and 41 were self-diagnosed with documented use of an 
antifungal agent. There were no significant differences in the incidence of VVC between the 
three study sites or the two vaccine arms so the data were combined for further analyses. The 
incidence of VVC did not vary significantly by race, age, or years of education (Table 6.1). 
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 Antimicrobial use was reported by 341 (52.5%) women at least once and at 605 (10.8%) 
of the follow-up visits. Women reported using a total of 699 antibiotic prescriptions for an 
overall antibiotic use rate of 81.2 per 100 woman-years of follow-up (95% CI: 75.4-87.5). Use of 
more than one antibiotic was reported at 75 visits; 2 at 52 visits, 3 at 21 visits, and 4 at 2 visits. 
The classes of antibiotics used are shown in Table 6.2. The most commonly reported antibiotics 
were β-lactams (30.8%), metronidazole (24.2%), and protein synthesis inhibitors (22.6%). The 
majority of antibiotics were used to treat genitourinary conditions (48.5%); primarily bacterial 
vaginosis (20.6%), urinary tract infections (13.3%), and sexually transmitted infections (10.9%). 
However, 26.2% of the antibiotic use was for the treatment of upper respiratory tract infections. 
 The unadjusted associations between antimicrobial use, contraceptive methods, sexual 
activity, and vaginal Lactobacillus colonization with VVC are shown in Table 6.3.  Women who 
denied antibiotic exposure since the prior visit had an incidence of VVC of 20 per 100 woman-
years (95% CI: 17-24), while women who reported any antibiotic use had an incidence of VVC 
of 52 per 100 woman-years (95% CI: 40-68, p<0.001). When antibiotic use was categorized  by 
mechanism of action, the incidence of VVC ranged between 17 per 100 to 70 per 100 women-
years with the highest incidence occurring among women who used β-lactams (penicillins, 
cephalosporins), followed by those who used metronidazole, and nucleic acid synthesis 
inhibitors (fluoroquinolones, nitrofurantoin, p<0.001). Among the 52 women who acquired VVC 
and had reported antibiotic use, the median duration of antibiotic therapy prior to the onset of 
symptoms was 5 days (range: 1-36 days), while the median time since first dose to onset of 
symptoms was 9 days (range: 1-63 days).  
 There was no significant difference in the incidence of VVC between women who did not 
use any or used non-barrier contraceptive methods (20 per 100 women-years), barrier methods 
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(25 per 100 women-years), and those who used oral contraceptives, intra-uterine devices 
containing levonorgestrel, the vaginal ring, transdermal patches, or implants (29 per 100 women-
years). Compared to women using other contraceptive methods, women who used DMPA had a 
lower VVC incidence of 8 per 100 women-years (95% CI: 4-16, p=0.01), Table 6.3. 
 There was an association between various measures of sexual activity and increased 
incidence of VVC (Table 6.3). Women who were sexually abstinent since their prior visit had an 
incidence of 12 per 100 woman-years while the incidence was 24 per 100 women-years among 
women with one male partner, and 56 per 100 women-years among those with 2 or  more 
partners (p=0.003). However, there was no significant dose-response relationship between 
frequency of sexual intercourse and VVC (data not shown). Finally, there was no association 
between vaginal Lactobacillus colonization at the prior visit, both any or hydrogen peroxide-
producing strains, and VVC (p=0.12 for both).  
 In the multivariable regression analyses, antimicrobial use, DMPA, and numbers of male 
sex partners were independently associated with VVC (Table 6.4). When antibiotic use was 
included in the model as a dichotomous variable (Model I), women who used any antibiotic were 
2.31 times more likely to acquire VVC (adjusted hazard ratio (aHR) =2.31, 95% CI: 1.67-3.19) 
compared to women who did not use antibiotics. When antibiotic use was categorized by 
mechanism of action (Model II), women who used β-lactams had a 3-fold increased risk of VVC 
(aHR =3.16, 95% CI: 2.06–4.86), while women who used metronidazole and nucleic acid 
synthesis inhibitors had a 2.4-fold increased risk (aHR=2.52, 95% CI: 1.40–4.53 and aHR=2.31, 
95% CI: 1.03–5.18, respectively). Macrolides, lincosamides, tetracyclines and sulfonamides 
were not significantly associated with an increased risk of VVC. The adjusted hazard ratio for β-
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lactams was significantly higher than that of sulfonamides and unknowns (p=0.047). However, 
the hazard ratios did not differ significantly among the other classes of antibiotics. 
 Compared with women who did not use any or used non-barrier contraceptive methods, 
women who used DMPA were 67% less likely to develop VVC (aHR=0.33, 95% CI: 0.12–0.90) 
(Model II). There was not a significant increased risk of VVC associated with oral 
contraceptives, intra-uterine devices containing levonorgestrel, the vaginal contraceptive ring, 
transdermal patches, or implants (aHR=1.07, 95% CI: 0.66–1.74) when compared to women that 
did not use any or used non-barrier contraceptives.  The frequency of antibiotic use was similar 
between women who used DMPA (9.3%) and those who did not (10.7%, p=0.22).  
 The risk of VVC increased with number of male sex partners since the prior visit. 
Compared to women who were sexually abstinent since the last visit, women with one partner 
were 2 times more likely to acquire VVC (aHR=2.05, 95% CI: 1.03–4.08) and women with 
multiple partners were 4.6 times more likely to acquire VVC (aHR=4.59, 95% CI: 1.87–11.28), 
Model II. These analyses were repeated using only the 164 clinician-diagnosed VVC episodes as 
outcomes, and the results were similar (Table 6.5). In this analysis, the association between the 
use of fluoroquinolones and nitrofurantoin and VVC was no longer statistically significant 
(p=0.060). The proportional hazards assumption was not violated for any of the covariates 
included in the final models (p>0.16). 
 
6.5 DISCUSSION 
 
This study suggests that antimicrobial use was associated with a 2.3-fold increased risk of VVC 
which confirms those of previous studies.41, 43 However, the magnitude of the association 
between antibiotic use and VVC varied by antibiotic class, with the highest risk being associated 
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with β-lactams, which was significantly different from the combined risk of VVC associated 
with sulfonamides. Metronidazole, fluoroquinolones, and nitrofurantoin were also associated 
with an increased risk of VVC acquisition, while other classes of antibiotics, including 
macrolides, lincosamides, tetracyclines, and sulfonamides were not associated with a significant 
increased risk of VVC. These results differ from those of Spinillo et al which did not report a 
difference in the risk of VVC among different antibiotic classes.43 The present study 
prospectively evaluated antibiotic use and its association with incident clinician- or self-
diagnosed VVC whereas the Spinillo et al study was retrospective in nature and evaluated 
prevalent culture-proven VVC. The contradicting results of the two studies may also be due to 
regional differences in antibiotic prescribing patterns. The antibiotic use rate among the women 
in this study was 81.2 per 100 person-years, which is considerably higher than the estimated 
national outpatient prescribing rate of 30 per 100 among adults in 2002.50 While the burden of 
antibiotic use in this population of reproductive-aged women was high, a quarter of the antibiotic 
use was for upper respiratory tract infections for which antibiotics are rarely recommended.79 
Since the results from the current study indicate that antibiotics increase the risk for acquiring 
VVC, clinicians should refrain from prescribing unnecessary antibiotics in women.  
 Although many consumer-oriented web sites and printed materials cite the dogma that 
oral contraceptives and other hormonal methods increase yeast vaginitis, in this population of 
sexually active women, VVC was not increased among women using hormonal contraceptive 
methods. Women using DMPA had a decreased risk of VVC, a finding consistent with those of 
Miller et al who reported a decrease in vaginal yeast colonization from 21% at baseline to 8% at 
3 and 6 months after initiation of DMPA use (P=0.02).96 However, our results differ from those 
of Baeten et al who reported no decrease in incident vaginal candidiasis among 251 African 
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women using DMPA.97 Since VVC is an estrogen-dependent condition,98 it is biologically 
plausible that DMPA would reduce VVC due to the hypoestrogenic effect of this contraceptive 
method. DMPA induces a profound suppression of estradiol levels via negative feedback on the 
hypothalamic-pituitary-ovarian axis, resulting in estradiol levels which may become as low as 
those observed in post-menopausal women.99 This concept is supported by animal model studies 
which have demonstrated that the presence of estrogen decreased the capacity of vaginal 
epithelial cells to inhibit the growth of Candida albicans in mice.100 To help determine whether a 
similar situation occurs in humans, future studies should evaluate the association between the 
incidence of VVC and contraceptive methods containing only progesterone and those also 
containing estrogen .  
 Although oral contraceptives were not associated with VVC in our study, Baeten et al 
reported an increased risk of vaginal candidiasis among sex workers in Africa using oral 
contraceptives. 97 However, differences in the study population and their sexual activity may 
account for this inconsistency since the risk of VVC increased with numbers of male sex partners 
in the current study.   
 Sexual activity, as measured by number of male sexual partners, was associated with 
VVC in our study, and there was a dose-response relationship with increasing numbers of 
partners. In contrast, there was no dose-response relationship with frequency of sexual 
intercourse. While previous studies have shown an association between various sexual behaviors 
and increased VVC, they did not find a significant association with numbers of sex partners.101-
103 The mechanisms by which increased numbers of sex partners increase risk of VVC deserves 
further study but it is plausible that sexual activity increases transfer of yeast from the mouth or 
86 
 
rectum to the vagina, and that having more partners increased the likelihood of exposure to a  
male partner colonized by yeast at these sites.      
 Because women vaginally colonized by lactobacilli have a decreased incidence of 
bacterial vaginosis, HIV, and other sexually transmitted pathogens,104-106 many have presumed 
that lactobacilli should also decrease the risk of VVC. Paradoxically, one study found that 
women with concurrent vaginal Lactobacillus colonization had a 4-fold increased risk of 
VVC.107 In contrast, there was no association between colonization by vaginal lactobacilli at the 
prior visit and VVC in this study which suggest that Lactobacillus colonization is neither 
protective nor a risk factor for VVC. Our results are consistent with those of Hawes et al who 
found that the presence of hydrogen peroxide-producing lactobacilli did not protect against 
acquisition of VVC in 182 women.105 While the effect of antibiotic use on colonization by 
lactobacilli was not assessed, penicillins and cephalopsorins which have activity against 
lactobacilli and metronidazole which does not, all were associated with an increased risk of yeast 
vaginitis so it is unlikely that the effect of antimicrobial use on vaginal lactobacilli colonization 
is important in the pathogenesis of VVC.  
 Major strengths of our study include the prospective longitudinal design and the large 
sample of 650 women with over 5500 visits. However, there are also limitations. VVC episodes 
were identified through participant reports; therefore the diagnosis of yeast vaginitis could not be 
confirmed. In addition, 20% of the VVC events were self-diagnosed. However, the associations 
of antibiotic use, contraceptive methods, and sexual activity with VVC remained unchanged 
when the analyses were restricted to clinician diagnosed VVC events. Antibiotic exposure in the 
last 2 months was ascertained by interview which is subject to recall error yet a r ecent study 
found 89% agreement between self-reported antibiotic use in the last 3 months and pharmacy 
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database records 87 Finally, this was a young, sexually active population which limits 
generalizability of results; results may not be applicable to adolescents, pregnant women, or 
older women.  
 This study suggests that the association of antibiotic use with increased VVC varies by 
antibiotic classes which may explain the inconsistencies of previous studies which have 
evaluated antibiotic use as a d ichotomous variable. The use of DMPA had a protective effect 
while other hormonal contraceptive methods, such as oral contraceptives, were not associated 
with VVC. While the etiology of VVC is complex, antibiotic therapy, number of male sex 
partners, and contraceptive choices influence the incidence of VVC. 
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6.7 TABLES 
 
Table 6.1 Association of enrollment characteristics with vulvovaginal candidiasis 
 
 No. of 
participants 
No. of 
VVC 
events 
Rate* of VVC 
(95% CI) 
Unadjusted HR 
(95% CI) 
P-value 
Site      
  Pittsburgh, PA 391 147 25 (21-29) Referent  
  Augusta, GA 212 50 21 (16-28) 0.86 (0.59-1.26) 0.44 
  Houston, TX 47 8 24 (12-49) 0.97 (0.35-2.69) 0.95 
      
Vaccine arm      
  Tetanus-diphtheria 330 114 26 (22-31) Referent  
  GBS type III 320 91 22 (18-26) 0.82 (0.58-1.16) 0.27 
      
Race      
  White 391 122 23 (20-28) Referent  
  Black 212 71 25 (20-32) 1.13 (0.77-1.66) 0.52 
 Other 47 12 21 (18-37) 0.91 (0.47-1.76) 0.77 
      
Age, years      
  18-19 67 15 17 (10-28) Referent  
  20-24 274 103 29 (24-35) 1.69 (0.92-3.13) 0.09 
  25-29 167 53 24 (18-31) 1.39 (0.70-2.76) 0.34 
  30-34 72 21 22 (15-34) 1.33 (0.60-2.94) 0.49 
  35-40 70 13 13 (8-23) 0.81 (0.33-1.97) 0.64 
      
Education, years      
  8-12 162 41 19 (14-26) Referent  
  13-16 347 119 26 (22-32) 1.35 (0.86-2.10) 0.19 
  17 or more 141 45 23 (17-31) 1.17 (0.69-1.97) 0.56 
VVC, vulvovaginal candidiasis; HR, hazard ratio; CI, confidence interval 
* Rate per 100 person-years 
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Table 6.2 Antibiotic use by class 
 
Antibiotic Class 
No. of Prescriptions 
Reported  
Antibiotic Use Rate* 
(95% CI) 
Total prescriptions 699 81.2 (75.4-87.5) 
   
β-lactams 215 (30.8%) 25.0 (21.9-28.5) 
  Penicillins 158 (22.6%) 18.4 (15.7-21.5) 
  Cephalosporins 57 (8.2%) 6.6 (5.1-8.6) 
   
Metronidazole 169 (24.2%) 19.6 (16.9-22.8) 
   
Protein synthesis inhibitors 158 (22.6%) 18.4 (15.7-21.5) 
  Macrolides 106 (15.2%) 12.3 (10.2-14.9) 
  Tetracyclines 42 (6.0%) 4.9 (3.6-6.6) 
  Lincosamides 10 (1.4%) 1.2 (0.6-2.2) 
   
Nucleic acid synthesis inhibitors 79 (11.3%) 9.2 (7.4-11.4) 
  Fluoroquinolones 61 (8.7%) 7.1 (5.5-9.1) 
  Nitrofurantoin 18 (2.6%) 2.1 (1.3-3.3) 
   
Others 78 (11.2%) 9.1 (7.3-11.3) 
  Sulfonamides 47 (6.7%) 5.5 (4.1-7.3) 
  Aminoglycosides 1 (0.1%) 0.1 (0.02-0.8) 
  Unknown 30 (4.3%) 3.5 (2.4-5.0) 
CI, confidence interval 
* Number of antibiotic uses per 100 person-years 
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Table 6.3 Association of antibiotic use, contraceptive methods, sexual activity, and vaginal 
Lactobacillus colonization with vulvovaginal candidiasis 
 
 
 
No. of VVC 
events 
Rate* of VVC 
(95% CI) 
Unadjusted 
HR (95% CI) 
P-value 
Antibiotic use since last visit     
  Any 52 52 (40-68) 2.47 (1.78-3.43) <0.001 
  None 153 20 (17-24) Referent  
     
Antibiotic use since last visit†     
  None 153 20 (17-24) Referent  
  β-lactams  25 70 (47-104) 3.20 (2.06-4.95) <0.001 
  Protein synthesis inhibitors  8 37 (19-75) 1.85 (0.87-3.90) 0.11 
  Metronidazole  11 55 (30-99) 2.74 (1.54-4.91) 0.001 
  Nucleic acid synthesis inhibitors  6 54 (24-119) 2.50 (1.11-5.63) 0.03 
  Others 2 17 (4-70) 0.81 (0.20-3.28) 0.77 
     
Contraception since last visit‡     
  None or non-barrier methods 34 20 (14-27) Referent  
  Barrier methods 45 25 (19-33) 1.27 (0.78-2.09) 0.34 
  Hormonal methods, not DMPA 119 29 (24-34) 1.43 (0.91-2.25) 0.12 
  DMPA 7 8 (4-16) 0.39 (0.15-1.06) 0.06 
     
New sex partner since last visit     
  Yes 27 43 (29-63) 1.91 (1.28-2.85) 0.002 
  No 178 22 (19-26) Referent  
     
Number of sex partners since last visit     
  None 12 12 (7-20) Referent  
  One 174 24 (21-28) 2.10 (1.07-4.13) 0.03 
  Two or more 19 56 (36-88) 4.84 (1.95-11.98) 0.001 
     
Vaginal Lactobacillus colonization at 
prior visit 
    
  Present 182 25 (22-29) 1.46 (0.91-2.33) 0.12 
  Absent 23 17 (12-26) Referent  
     
Vaginal H202-producing Lactobacillus 
colonization at prior visit 
    
  Present 156 26 (22-30) 1.35 (0.92-1.97) 0.12 
  Absent 49 19 (15-26) Referent  
VVC, vulvovaginal candidiasis; HR, hazard ratio; CI, confidence interval; DMPA, depot 
medroxyprogesterone acetate 
* Rate per 100 person-years 
† β-lactams (penicillins, cephalosporins); protein synthesis inhibitors (macrolides, lincosamides, 
tetracyclines); nucleic acid synthesis inhibitors (fluoroquinolones, nitrofurantoin); others (sulfonamides, 
unknown). 
‡ Non-barrier methods (spermicides, tubal ligations, copper intrauterine devices); barrier methods 
(condoms, diaphragms, cervical caps); hormonal methods, not DMPA (oral contraceptive tablets, vaginal 
rings, intrauterine devices containing levonorgestrel, transdermal patches, implants).  
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Table 6.4 Independent risk factors for vulvovaginal candidiasis, both clinician and self-
diagnosed events (N=5599 Visits, n=205 events)  
 
 Adjusted* 
Hazards Ratio 
95% Confidence 
Interval 
P-value 
Model I    
    
  Any antibiotic use since last visit 2.31 1.67 – 3.17 <0.001 
    
  Contraception since last visit‡    
    None or non-barrier methods 1.00 referent  
    Barrier methods 0.98 0.58 – 1.66 0.94 
    Hormonal methods, not DMPA 1.07 0.65 – 1.74 0.80 
    DMPA 0.33 0.12 – 0.90 0.031 
    
  Number of sexual partners since last visit    
    None 1.00 referent  
    One 2.02 1.02 – 4.04 0.045 
    Two or more 4.45 1.80 – 11.00 0.001 
    
Model II    
    
  Antibiotic use since last visit†    
    None 1.00 referent  
    β-lactams  3.16 2.06 – 4.86 <0.001 
    Protein synthesis inhibitors  1.63 0.78 – 3.40 0.19 
    Metronidazole  2.52 1.40 – 4.53 0.002 
    Nucleic acid synthesis inhibitors  2.31 1.03 – 5.18 0.042 
    Others 0.72 0.18 – 2.97 0.65 
    
  Contraception since last visit‡    
    None or non-barrier methods 1.00 referent  
    Barrier methods 0.99 0.59 – 1.66 0.98 
    Hormonal methods, not DMPA 1.07 0.66 – 1.74 0.77 
    DMPA 0.33 0.12 – 0.90 0.030 
    
  Number of sexual partners since last visit    
    None 1.00 referent  
    One 2.05 1.03– 4.08 0.041 
    Two or more 4.59 1.87 – 11.28 0.001 
DMPA, depot medroxyprogesterone acetate 
* Adjusted hazards ratio obtained with Andersen-Gill proportional hazards regression model including 
age, antimicrobial use, contraceptive method, and number of sexual partners. 
† β-lactams (penicillins, cephalosporins); protein synthesis inhibitors (macrolides, lincosamides, 
tetracyclines); nucleic acid synthesis inhibitors (fluoroquinolones, nitrofurantoin); others (sulfonamides, 
unknown). 
‡ Non-barrier methods (spermicides, tubal ligations, copper intrauterine devices); barrier methods 
(condoms, diaphragms, cervical caps); hormonal methods, not DMPA (oral contraceptive tablets, vaginal 
rings, intrauterine devices containing levonorgestrel, transdermal patches, implants).  
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Table 6.5 Independent risk factors for vulvovaginal candidiasis, restricted to clinician-
diagnosed events (N=5599 Visits, n=164 events) 
 
 Adjusted* 
Hazards Ratio 
95% Confidence 
Interval 
P-value 
Model I    
    
  Any antibiotic use since last visit 2.32 1.62 – 3.31 <0.001 
    
  Contraception since last visit‡    
    None or non-barrier methods 1.00 referent  
    Barrier methods 0.74 0.42 – 1.30 0.30 
    Hormonal methods, not DMPA 0.97 0.58 – 1.61 0.90 
    DMPA 0.26 0.08 – 0.78 0.017 
    
  Number of sexual partners since last visit    
    None 1.00 Referent  
    One 2.36 1.16 – 4.81 0.018 
    Two or more 3.66 1.39 – 9.65 0.009 
    
Model II    
    
  Antibiotic use since last visit†    
    None 1.00 referent  
    β-lactams  3.29 2.09 – 5.18 <0.001 
    Protein synthesis inhibitors  1.55 0.63 – 3.80 0.34 
    Metronidazole  2.59 1.34 – 5.00 0.005 
    Nucleic acid synthesis inhibitors  2.38 0.96 – 5.90 0.060 
    Others 0.46 0.06 – 3.32 0.44 
    
  Contraception since last visit‡    
    None or non-barrier methods 1.00 Referent  
    Barrier methods 0.76 0.43 – 1.32 0.32 
    Hormonal methods, not DMPA 0.97 0.59 – 1.62 0.92 
    DMPA 0.26 0.08 – 0.76 0.016 
    
  Number of sexual partners since last visit    
    None 1.00 Referent  
    One 2.39 1.17 – 4.86 0.016 
    Two or more 3.81 1.46 – 9.95 0.006 
DMPA, depot medroxyprogesterone acetate 
* Adjusted hazards ratio obtained with Andersen-Gill proportional hazards regression model including 
age, antimicrobial use, contraceptive method, and number of sexual partners. 
† β-lactams (penicillins, cephalosporins); protein synthesis inhibitors (macrolides, lincosamides, 
tetracyclines); nucleic acid synthesis inhibitors (fluoroquinolones, nitrofurantoin); others (sulfonamides, 
unknown). 
‡ Non-barrier methods (spermicides, tubal ligations, copper intrauterine devices); barrier methods 
(condoms, diaphragms, cervical caps); hormonal methods, not DMPA (oral contraceptive tablets, vaginal 
rings, intrauterine devices containing levonorgestrel, transdermal patches, implants). 
93 
 
7.0 DISCUSSION 
 
 
7.1 SUMMARY OF FINDINGS 
 
The objectives of this research were to describe the burden of antibiotic use in young women, to 
assess the impact of antibiotics on vaginal and rectal lactobacilli, and to evaluate the association 
between antibiotic use and incident yeast vaginitis.  Antibiotic use was widespread in this 
population of relatively healthy, reproductive-aged, non-pregnant women. The majority of the 
antibiotic use was for the treatment of genitourinary infections.  Factors associated with use of 
antibiotics for indications other than upper respiratory tract infections included having more 
sexual partners, black race, and the absence of predominant vaginal lactobacilli, which are 
known risk factors for genital tract infections. However, about one in five antibiotics prescribed 
were used to treat upper respiratory tract illnesses for which antibiotics provide little therapeutic 
benefit. The treatment of upper respiratory tract infections was the major contributor to exposure 
of women to broad spectrum and β-lactam antibiotics in this study. Factors associated with 
possible inappropriate antibiotic use were being white and older age which may be markers for 
socio-economic factors associated with differential access to care. Paradoxically, although black 
women in this study were more likely to have received antibiotics, they were less likely to have 
been prescribed antibiotics inappropriately for upper respiratory tract infections. 
 A major concern related to the inappropriate use of antibiotics is that this use will result 
in the selection of antibiotic resistant microbes. The present study did not evaluate the impact of 
antibiotic use on the antibiotic susceptibility of pathogens, but rather focused on the impact of 
antibiotic use on lactobacilli, which are the predominant members of the healthy vaginal 
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microbiome. Because lactobacilli are gram positive bacteria having susceptibility to several 
antibiotic classes, it is biologically plausible that antibiotic use could have a profound impact on 
colonization by this beneficial microbe. However, this study showed that many antibiotics had 
no measurable effect on colonization by lactobacilli, and the effect was limited to the use of β-
lactam agents. For this study, we focused on the species of lactobacilli which produce hydrogen 
peroxide because it has been shown that colonization by hydrogen peroxide-producing 
lactobacilli is associated with a reduced risk of acquiring bacterial vaginosis. There was a 
significant reduction in vaginal and rectal colonization by hydrogen peroxide-producing 
lactobacilli following the use of β-lactam antibiotics, while other classes of antibiotics or overall 
self-reported antibiotic use were not associated with decreased Lactobacillus colonization in our 
population of women. The class-specific effect of β-lactam antibiotics likely accounts for the 
inconsistencies in the published literature which have reported on the impact of antibiotic use on 
vaginal lactobacilli.  
 All of the published studies which have evaluated the impact of antibiotic use on 
colonization by lactobacilli have focused on the vagina, since this microorganism is the 
predominant microorganism present in this ecosystem. A key strength of this research was the 
inclusion of rectal swabs which allowed for the simultaneous detection of lactobacilli in both 
body sites at the same sampling interval. A novel finding from the present study was that use of 
β-lactams reduced rectal colonization by hydrogen peroxide-producing lactobacilli to a similar 
degree as that observed in the vagina. However, the impact of β-lactam use on rectal colonization 
persisted for longer than that observed for the vagina. Only β-lactam use in the previous two 
weeks was associated with reduced vaginal colonization. These results suggest that the 
disruption of Lactobacillus colonization associated with the use of β-lactam antibiotics persists 
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in the rectum for a longer period of time than in the vagina, which is consistent with the concept 
that there is greater perturbation of the gut microflora following antibiotic use than the 
microflora at other anatomical sites.  
 There are several different species of lactobacilli present in the vaginal and rectal 
microbiome. In this population of reproductive-aged women, the use of β-lactam antibiotics was 
associated with reduced colonization by any hydrogen peroxide-producing lactobacilli. Another 
novel contribution of the present study was the identification of the individual species present in 
the vagina and rectum in order to assess whether the impact of antibiotic usage on colonization 
was species- or genus-specific. There was variability in the inhibitory effect of β-lactam 
antibiotics on the primary hydrogen peroxide-producing species, L. crispatus, L.jensenii, and L. 
gasseri. While the use of β-lactams was associated with decreased colonization by L. crispatus in 
the rectum but not in the vagina, recent β-lactam use was associated with marked decreases in 
both vaginal and rectal Lactobacillus colonization in women whose predominant hydrogen 
peroxide-producing Lactobacillus species were L. jensenii or L. gasseri. 
 The final set of analyses evaluated whether the high burden of antibiotic use and 
disruption of the vaginal microbiota was associated with increased numbers of symptomatic 
yeast infections. Self-reported antibiotic use was associated more than a 2-fold increased risk of 
incident vulvovaginal candidiasis in this cohort of non-pregnant, reproductive-aged women. 
However, the magnitude of the association between antibiotic use and vulvovaginal candidiasis 
varied by antibiotic class, with the highest risk being associated with β-lactams, followed by 
metronidazole, and nucleic acid synthesis inhibitors (fluoroquinolones and nitrofurantoin).  Other 
classes of antibiotics, including macrolides, lincosamides, tetracyclines, and sulfonamides were 
not associated with a significant increased risk of vulvovaginal candidiasis which may explain 
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the inconsistencies of previous studies which have evaluated antibiotic use as a dichotomous 
variable. 
 In summary, the analyses conducted as part of this dissertation have confirmed that 
antibiotic use is common in young women and extended our knowledge by showing that the 
preponderance of antibiotic usage is for the treatment of genitourinary tract infections. However, 
the present study did find an increased prevalence of inappropriate use of antibiotics for upper 
respiratory tract infections among older and white women. These data suggest that programs to 
reduce antibiotic use will require multiple strategies comprising of reduction in treatable 
genitourinary tract infections and reducing the use of antibiotics for upper respiratory tract 
infections. Our data also suggest that the use of β-lactam antibiotics deserves special attention in 
the efforts to reduce inappropriate use of antibiotics since this class of antibiotics was associated 
with decreased colonization by beneficial lactobacilli and the greatest increase in incident yeast 
vaginitis. Together, these analyses have provided new insights into the usage of antibiotics and 
their broad impact on the health of reproductive-aged women.  
 
7.2 FUTURE RESEARCH 
 
The research presented here utilized data obtained as part of a randomized clinical trial, and thus 
the study was not optimally designed to evaluate the impact of antibiotic use on Lactobacillus 
colonization and incident yeast vaginitis. Future prospective studies could expand upon the 
current research by enrolling women who are prescribed an antibiotic for any indication at an 
office or clinic visit. Vaginal and rectal samples for microbiological cultures could then be 
obtained prior to the initiation of antibiotic therapy, followed by the collection of daily samples 
for the first 2-3 weeks, and then weekly samples for two months. This sampling schedule would 
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enable evaluation of the vaginal and rectal microflora prior to initiation and after cessation of 
antibiotic therapy in order to assess the acute effects of specific antibiotics on each microbiome 
and also estimate the length of the impact of antibiotic use. In addition, this type of study design 
would allow for proactive clinical assessments of vaginal infections, such as yeast vaginitis and 
bacterial vaginosis, which may lead to a better understanding of the mechanisms by which 
antibiotics may enhance the development of these conditions. 
 
7.3 PUBLIC HEALTH SIGNIFICANCE 
 
Minimizing the inappropriate use of antibiotics is a public health priority. Since studies indicate 
a high prevalence of over-prescribing antibiotics for the treatment of upper respiratory tract 
infections, many antibiotic stewardship programs focus on reducing inappropriate antibiotic use 
for the treatment of these conditions. Reducing unnecessary antibiotic treatment of upper 
respiratory tract infections would reduce exposure to broad-spectrum antibiotics and to β-lactams 
since they were primarily used to treat these illnesses in our population of young women. This 
would have a beneficial impact on public health for several reasons. The use of β-lactams was 
the only class of antibiotics associated with decreased colonization by hydrogen peroxide-
producing lactobacilli. Women lacking hydrogen-producing lactobacilli in the vagina and/or 
rectum have an increased incidence of bacterial vaginosis, which subsequently increases the risk 
of acquiring other genital infections such as HIV, Neisseria gonorrhoeae, Chlamydia 
trachomatis, and Trichomonas vaginalis. In our population of women, β-lactams were also 
associated with the highest risk of acquiring yeast vaginitis, the second most common cause of 
vaginitis after bacterial vaginosis. Finally, the use of broad-spectrum antibiotics contributes to 
the development of antibiotic-resistant infections. Therefore, it would be important to tailor 
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programs promoting the judicious use of antibiotics for the treatment of upper respiratory tract 
infections to women and their healthcare providers to increase awareness that the inappropriate 
use of antibiotics may disrupt the normal vaginal and rectal microbiota and increase 
susceptibility to other infections. However, targeting only the treatment of upper respiratory tract 
infections would have little impact on the overall antibiotic use in reproductive-aged women 
since the majority of the antibiotic use was for the treatment of genitourinary conditions. 
Prevention efforts on reducing acquisition of sexually transmitted infections would have the 
cross benefit of also reducing antibiotic exposure in women.  
 Yeast vaginitis accounts for millions of office visits each year for reproductive aged 
women. Overall antibiotic use was associated with yeast vaginitis which confirms many patient 
and clinician perceptions. However the risk associated with increased incidence of vulvovaginal 
candidiasis varied by antibiotic class, even after accounting for other risk factors (sexual activity 
and contraception). The pathophysiology of vulvovaginal candidiasis is complex and poorly 
understood even after decades of research. The classes of antibiotics that were associated with 
vulvovaginal candidiasis had different mechanisms of action which suggests that they may be 
affecting a different component in the physiological pathway. It is likely that antibiotic use 
creates a temporary imbalance in the vaginal microbiome, allowing for proliferation of 
indigenous yeasts. Sexual activity was also associated with vulvovaginal candidiasis, which not 
only creates an imbalance in the vaginal ecosystem, but allows for transfer of yeasts from the 
rectum or from a colonized sexual partner to the vagina. These findings suggest that women with 
a history of recurrent yeast vaginitis should be advised that antibiotic use may increase their risk 
of vulvovaginal infections. 
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 The introduction of antibiotics in clinical care led to a significant reduction in mortality 
due to infectious diseases in the US in the early 1900s.1 However, the overuse of antibiotics has 
since contributed to the emergence of antibiotic resistant bacteria which are estimated to cause 
more than 2 m illion illnesses and 23,000 de aths per year.3 While the primary objective in 
reducing unnecessary exposure to antibiotics is to curb the emergence and spread of antibiotic 
resistant pathogens, reducing exposure to antibiotics, particularly to β-lactams which is the most 
common class of antibiotics prescribed in the US, will have the additional benefit of minimizing 
the adverse effects of antibiotic use on the beneficial indigenous vaginal and rectal microflora of 
reproductive-aged women.  
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